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Abstract

Bacteria are well known to cause chronic infections in humans by entering dormancy and
by developing biofilms. These mechanisms allow bacteria to exhibit antibiotic tolerance
and relapse to an active virulent state when the antibiotic treatments are discontinued.
During bacterial invasions, the host immune cells secrete special signaling proteins,
known as cytokines which orchestrate events leading to human immune response and
elimination of bacterial pathogens. However, compared to the well documented activities
of cytokines in immune reaction, little is known about the direct effects of cytokines on
bacterial cells.
In this study, we focused on granulocyte macrophage colony-stimulating factor
(GM-CSF), a cytokine produced by macrophages, T-cells, endothelial cells, and
fibroblasts. We chose Pseudomonas aeruginosa as a model bacterium. It is an
opportunistic pathogenic bacterium and a major cause of nosocomial infections in
individuals with compromised immune systems and cystic fibrosis (CF) patients. We
show for the first time that GM-CSF can sensitize the persister cells of P. aeruginosa
PAO1 to multiple antibiotics including ciprofloxacin, tobramycin, tetracycline, and
gentamicin. The mucoid variant, P. aeruginosa PDO300 was also sensitized by GM-CSF
to tobramycin in the presence of alginate lyase. In addition, GM-CSF sensitized the
biofilm cells of P. aeruginosa PAO1 and PDO300 to tobramycin in presence of biofilm
matrix degrading enzymes DNase I and alginate lyase, respectively. In comparison, the
normal cells of P. aeruginosa and the non-pathogenic Escherichia coli K12 persister cells
were not affected by GM-CSF.

DNA microarray and qPCR analyses revealed that GM-CSF induced flagella and
pyocin associated genes in persister cells of P. aeruginosa PAO1, while the same genes
in normal cells did not show significant change. Using co-immunoprecipitation (co-IP)
and cross-linking, GM-CSF was found to interact with the protein FliC (flagellin).
Deletion of fliC gene abolished the effects of GM-CSF on P. aeruginosa persister cells,
which was restored by complementation of the fliC gene. Overall, the findings from this
study suggest that cytokines have a direct interaction with bacterial cells and disturb their
persistence. The results are helpful for understanding bacterial physiology and for
developing new persistence control methods.

Keywords: GM-CSF, persister cells, biofilms, Pseudomonas aeruginosa, antibiotic
tolerance, flagella, pyocins.
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CHAPTER 1

MOTIVATION, HYPOTHESIS, AND OBJECTIVES
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1.1 Motivation
Bacterial infections are caused by pathogenic bacteria through multiple-factorial
processes involving the increase in bacterial cell population, release of virulence factors,
and the availability of host immune factors and antimicrobials 1,2. Infections are initiated
when the pathogenic bacteria reach their target site, multiply rapidly, acquire nutrients
from the host, survive the attack by the host’s immune system, and progress into disease
with damage to the host’s vital functions 3. Previous studies on bacterial virulence
factors, toxins, endotoxins, transmission, and target sites in the past decades led to the
discovery of antibiotics for controlling bacterial infections and diseases 4. Common
modes of antibiotic action on bacteria include the inhibition of cell wall synthesis, protein
synthesis, and DNA replication/repair 5,6. Antibiotics are broadly classified into betalactams, aminoglycosides, quinolones, sulfonamides, and macrolides, based on their
modes of action 5.
The development of antibiotics since 1940s drastically reduced bacterial
infections and patient fatality rate 7. However, due to overuse of antibiotics, strains of
bacteria began acquiring antibiotic resistance, which is recognized as a great threat to
human health worldwide 7-9. In the North America, nearly 2 million people develop
hospital-acquired infections (HAIs) per year and at least 23,000 deaths are caused
directly by antibiotic-resistant infections (Antibiotic Resistance Threats in the United
States 2013, CDC report). Antibiotic resistance also places a huge economic burden on
our healthcare system with an annual cost estimated as $21 to $34 billion in the U.S.
along with more than 8 million additional days of hospital stay (Antimicrobial
Resistance: Global Report on Surveillance 2014, WHO). With increasing damage to the
2

healthcare and economy caused by antibiotic resistant infections, there is an urgent need
to find novel methods to control persistent bacteria.

1.2 Hypothesis and Research objectives
Cytokines, the signaling protein molecules secreted by immune cells play a significant
role in protection against bacterial and viral infections 10. Direct interactions between
bacteria and cytokines haven’t been studied extensively. Kanangat et al. 11 reported that
intracellular bacterial growth of the pathogens Staphylococcus aureus, P. aeruginosa, and
Acinetobacter sp. changed with concentration of IL-1β, IL-6, and TNF-α. Recently, the
use of immunotherapeutic agents like IL-12 and recombinant GM-CSF is being explored
for the treatment of drug resistant Tuberculosis (TB) caused by Mycobacterium
tuberculosis 12. The main focus of our study is the effects of GM-CSF on P. aeruginosa.
We hypothesize that GM-CSF can sensitize P. aeruginosa persister cells to antibiotics
through interaction with specific targets in this bacterium. This study has the following
aims:

Aim 1 (Chapter 3): To test the effects of GM-CSF on planktonic cells and biofilms of
P. aeruginosa PAO1, PDO300, and E. coli K12 in the presence and absence of
representative antibiotics (ciprofloxacin, tobramycin, tetracycline and gentamicin).
The results showed that GM-CSF can sensitize P. aeruginosa persister cells to multiple
antibiotics. Moreover, after addition of enzymes like alginate lyase and DNase I, GM-
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CSF and antibiotics displayed synergistic killing effects on biofilm cells of P.
aeruginosa.
Aim 2 (Chapter 4): To understand the effects of GM-CSF on gene expression in P.
aeruginosa PAO1. DNA microarrays and quantitative real-time PCR were used to
identify the genes induced or repressed by GM-CSF. After categorizing the genes
according to their functions, potential targets were selected and mutant strains were tested
with GM-CSF and antibiotics. The comparative studies between normal and persister
cells revealed that treatment with GM-CSF induced pyocin and flagella genes in P.
aeruginosa persisters, which is not observed in normal cells. Next, to understand how
binding of GM-CSF with its targets affects the persister cells of P. aeruginosa PAO1,
some representative genes found in our microarray studies were characterized. The
induced pyocin production after GM-CSF treatment was explored by using R2-pyocinproducing P. aeruginosa PAO1, and the R2-pyocin-sensitive strain, P. aeruginosa PAK.

Aim 3 (Chapter 5): To characterize the interaction between GM-CSF and potential
cellular targets in P. aeruginosa PAO1. The upregulation of flagellar genes by GMCSF indicated possible role of flagella in the persister control by GM-CSF. Using coimmunoprecipitation (co-IP) and cross-linking experiments, GM-CSF was found to
interact with FliC of P. aeruginosa. Consistently, deletion of the fliC gene abolished the
activity of GM-CSF, which was restored in the strain complemented with plasmid-borne
fliC. The tests with motA and motD mutants along with motility inhibiting agents
indicated that GM-CSF is more effective in interaction with resting flagella.
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2.1 Bacterial persistence
First described by Joseph Bigger in the early 1940s 1, persister cells are small
subpopulations of dormant phenotypic variants, which can be found in virtually all
bacterial cultures 1. Recent research has shown that persister cells play important roles in
intrinsic antibiotic resistance of bacteria 2 . The dormant nature of persister cells allows
this subpopulation to survive the attack of essentially all antibiotics 3. Balaban et al. 4
demonstrated by microscopic observation of individual bacterial cells grown in
microfluidic devices that persisters have a significantly reduced growth. Thus, when an
antibiotic therapy is stopped, the surviving persisters can relapse to normal cells, causing
chronic infections with recurring symptoms.
Because persisters are phenotypic variants rather than genetic mutants, these
cells can revert to normal cells upon inoculation of new culture 4. Antibiotic tolerance
differs from antibiotic resistance as it is not caused by mutations but rather by a small
bacterial population existing in a transient, dormant state 5. Moreover, persisters have the
ability to shield themselves from recognition and elimination by the host immune system
by hiding in locations like biofilms (e.g. Pseudomonas aeruginosa ), central nervous
system (e.g. Treponema pallidum ), macrophages or granulomas (e.g. Mycobacterium
tuberculosis ), stomach (e.g. Helicobacter pylori ), gall bladder ( e.g. Salmonella typhi ),
nose (e.g. Staphylococcus aureus ), etc. 6. The significant increase in the frequency of
persister formation in biofilms can partially explain the biofilm associated tolerance to
antibiotics 7. Given the high level antibiotic tolerance of persister cells and the pathogenic
infections, the ways to control and tackle their emergence and progress need to be
explored.
8

Figure 2.1 Schematic diagram of bacterial persistence. Green cells indicate normal
cells, red cells indicate persister cells. (A) Bacterial cells in a culture, (B) Cell lysis of
normal cells after antibiotic treatment, (C) Survival of persister cells in presence of
antibiotics, which revert to normal state and repopulate due to antibiotic deprivation and
favorable conditions for growth.

2.1.1 Toxin-Antitoxin system
Although not fully understood, persister formation has been constantly linked to toxinantitoxin (TA) modules, which are ubiquitous in bacterial chromosomes and are involved
in bacterial stress response 8. These TA modules encode a “toxin” that disrupts cellular
processes and a corresponding “antitoxin” that neutralizes the toxin 8,9. Five types of TA
systems have been discovered to date and are described in Table 2.1. These TA systems
include type I and III, where the antitoxins are RNAs that inhibit the toxin translation or
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activity; and type II, IV, and V, where the antitoxins are proteins that inhibit toxin
activity, counterbalance toxin activity or inhibit toxin synthesis 10.
Besides persistence, TA systems are also involved in the regulation of bacterial
motility, biofilm formation, and quorum sensing 9. Quorum sensing is a process of cellcell communication that involves regulation of gene expression in response to
fluctuations in cell-population density. Autoinducers are the extracellular signaling
molecules that are produced during quorum sensing 11,12. At low cell density, these
autoinducers are below detectable concentrations, whereas the autoinducers reach a high
concentrations at high cell density, leading to their detection and response 11. The
production is followed by their detection by receptors existing in bacterial cytoplasm or
membrane 11. The detection of autoinducers causes activation of gene expression for
group behaviors and further production of autoinducers 11,13. A vast majority of Gramnegative bacteria use acylated homoserine lactones (AHL) as autoinducers, and Grampositive bacteria use processed oligo-peptides for signaling 12,13. The other mechanisms
involved in persister formation include SOS response to DNA damage, nutrient
transition, amino acid starvation, oxidative stress, quorum signaling, indole signaling, and
other stresses 14,15. A variety of bacterial species produce large quantities of intercellular
signal molecules known as indoles, which control bacterial physiological activities like
plasmid stability, drug resistance, virulence, biofilm formation, and cell-cycle regulation
16-18

. By understanding the diverse pathways through which bacterial persistence is

achieved, potential ways to control persister cells can be found.
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Table 2.1 Currently known types of TA systems.
TA

Toxin

Antitoxin

system

Mode of

Examples

References

Action

Type I

Protein

RNA

Antitoxin, a
small antisense
RNA, basepairs with the
toxin encoding
mRNA.

BsrG/SR4,
Hok/Sok,
Tisb/IstR,
SymER, Ldr/Rdl,
Ibs/Sib,
Shob/OhsC,
Zor/Orz

Jahn et al. 19,
Gerdes et al. 20,
Vogel et al. 21,
Kawano 22,
Fozo 23,
Fozo 23,
Fozo 23

Type II

Protein

Protein

Antitoxin, an
unstable
protein, binds
to the toxin and
neutralizes it.

MazE/MazF,

Engelberg-Kulka et
al. 24,
Pederson et al. 25,
Kamada et al. 26,
Wang et al. 27,
Hansen et al. 28,
Zhang et al. 29

RelE/RelB,
YefM/YoeB,
MqsR/MqsA,
HipB/HipA,
VapB/VapC.

Type III

Protein

RNA

Antitoxin, a
small antisense
RNA, directly
binds with the
toxin and
neutralizes it.

ToxI/ToxN,
CptI/CptN,
TenpI/TenpN

Fineran et al. 30,
Blower et al. 31,
Blower et al. 31

Type IV

Protein

Protein

Antitoxin, a
protein,
interferes with
binding of the
toxin to its
target.

CbtA/CbtB

Masuda et al. 32

Type V

Protein

Protein

Antitoxin, a
protein, cleaves
toxin mRNA
preventing
toxin
translation.

GhoS/GhoT

Wang et al. 33
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Consistently, genes encoding for TA modules have been found upregulated in
the persister cells of Escherichia coli, compared to normal cells, according to the report
by Shah et al. 34. Deletion of the hipBA module led to a sharp reduction in the number of
persister cells (by 10-100 fold in stationary cultures) 35. Dorr et al. 36 reported that
knocking out SOS-TA locus tisAB/istR significantly reduced the tolerance of persister
cells to the antibiotic ciprofloxacin by 10-100 fold. As shown by Jayaraman et al.6,
persister formation is also stochastic in nature and is believed to be a strategy for cells to
reserve a small fraction of bacterial population for possible, unavoidable environmental
stresses. To date, two types of persister cells have been reported: type I persisters are
non-growing cells formed in response to stress factors mostly in stationary phase, while
type II persisters are slowly growing persisters formed in exponential phase by
phenotypic switch in the absence of stress factors and can revert to normal cells and
regrow 4,37. Zhang et al.38 studied persisters in tuberculosis (TB) and established a YinYang model of persisters and latent infections. The model described reverters as a small
population of non-growing or slowly growing persisters in exponential phase which
offers resistance during latent infection, while the “stem” persisters are described as small
population in stationary phase with the ability to cause reactivation 38. The dormancy and
antibiotic tolerance of persister cells as well as their capabilities to relapse to normal cells
pose a major challenge to the treatment of infectious diseases 2.

2.1.2 Controlling bacterial persistence
Persisters pose significant hindrance to complete eradication of bacterial infections, due
to their ability to survive multiple stress conditions 39. Controlling persister cells is
12

considered as a powerful strategy to reduce or eliminate the occurrence of chronic
infections. Some of the methods that have been studied to control bacterial persister cells
are discussed in Table 2.2 which includes waking-up persister cells, persister-specific
antibiotics, combination therapies, and inducing reactive oxygen species (ROS)
production etc.

Table 2.2 Some known methods to control bacterial persistence.
Method

Mechanism

Species

References

Metaboliteenabled killing
strategy

Aminoglycosides in combination
with specific proton motive force
(PMF)-stimulating metabolites.

Escherichia coli,
Staphylococcus aureus

Allison et al. 40

Antimicrobial
peptides

Bacterial membrane disruption.

Escherichia coli

Chen et al. 41

Stimulating
reactive oxygen
species (ROS)
production

Increasing ROS via an NADHdependent redox cycling pathway by
the antibiotic clofazimine.

Mycobacterium
smegmatis

Grant et al. 42

Stimulating
reactive
nitrogen
intermediates
(RNI)
production

Exogenous nitric oxide (NO) at
sublethal concentrations increases
RNI accumulation, leading to
dispersal of persistent biofilms and
improved tobramycin susceptibility.

Pseudomonas
aeruginosa

Barraud et al. 43

Protease
activating
antibiotic

Acyldepsipeptide antibiotic (ADEP4)
activates the ClpP protease and
causes extensive protein degradation.
ADEP4 in combination with
Rifampicin or linezolid eradicates
persisters.

Staphylococcus aureus

Conlon et al. 44

Silver and
antibiotics
combinations

Silver ions induce formation of
hydroxyl radical and increase
membrane permeability through

Escherichia coli

MoronesRamirez et al. 45
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disruption of disulfide bond
formation and misfolded protein
secretion.
Weak
electrochemical
currents and
antibiotic
synergy

Low-level direct currents (DCs) and
release of metal ions in presence of
an electric field have a bacteriostatic
effect and enhance effects of
aminoglycoside tobramycin.

Pseudomonas
aeruginosa

Niepa et al. 46

Persisterspecific
targeting

Metronidazole (MTZ), an antibiotic
that causes DNA damage in persister
cells only in hypoxic environments.

Mycobacterium
tuberculosis

Lin et al. 47

Pyrazinamide(PZA), an antibiotic
enters bacteria through passive
diffusion. It is more active against
persister cells due to slowed down
energy production and efflux pump
activities, which leads to
accumulation of toxic pyrazinoic acid
(POA).

Mycobacterium
tuberculosis

Zhang et al. 48

3-[4-(4-methoxyphenyl)piperazin-1yl]piperidin-4-yl biphenyl-4carboxylate (C10), a chemical kills
persister cells and reduces the
persister frequency by waking up and
reverting them to antibiotic-sensitive
cells.

Escherichia coli,
Pseudomonas
aeruginosa

Engineered
prototypical
persisterspecific
antibiotic

Pentobra, a multifunctional antibiotic
that combines membrane activity
with protein synthesis inhibition. The
antibiotic is engineered by addition
of 12 amino acids to tobramycin.

Escherichia coli
Staphylococcus aureus

Schmidt et al. 50

Triggering
persister wakeup by nutrient
sources

Addition of mannitol, a carbon
source improves the efficacy of
aminoglycoside tobramycin by
reverting the persister cells to normal
metabolically active cells.

Pseudomonas
aeruginosa

Barraud et al. 51

Quorum sensing
inhibition

(Z)-4-bromo-5-(bromomethylene)-3methylfuran-2(5H)-one (BF8), a
quorum sensing inhibitor reverts
antibiotic tolerance of persister cells.

Pseudomonas
aeruginosa

Pan et al. 52
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Kim et al. 49

In spite of some promising studies and findings to tackle bacterial persister cells, much
remains to be understood about the biology of persisters. There are limitations with
considering individual persister cells for transcriptomic and proteomic profiling, sensitive
diagnosis of latent infections harboring dormant persister cells, establishing relevant
models for persistence to conduct mechanistic studies of in vivo conditions, analysis of
host response to persister-specific targeting, etc. It will be interesting to identify host
immune mechanisms during latent infections, and potentially develop useful
immunotherapeutic treatments that can alter the microenvironments required for persister
survivals and eventually eradicate persister cells.

2.2 Bacterial biofilms
Persister population increases when a culture enters stationary phase or when cells form a
biofilm, which is a complex community of cells growing on a surface with the protection
of an extracellular matrix secreted by the attached cells 53. Biofilms account for 80% of
chronic infections in humans diseases 53. The biofilm infections are 10 to 1000 times
more resistant to antibiotic effects 54. For example, Pseudomonas aeruginosa and
Staphylococcus epidermidis are known to form biofilms which cause chronic infections
in patients suffering from cystic fibrosis and infected surgical implants respectively 7.
Biofilm structures are complex with structural heterogeneity, genetic diversity, complex
community interactions, and an extracellular matrix of polymeric substances 53.
The extracellular polymeric substances (EPS) consist of polysaccharides, and in some
cases nucleic acids, proteins, lipids, biosurfactants, bacterial flagella and pili 55. The
biofilm matrix can limit the penetration of antibiotics and immune factors leading to
15

recalcitrance of infections 2. Biofilms are formed on both biotic and abiotic surfaces,
making them ubiquitous in nature and potent reservoirs of chronic infections 56.
The polymeric substances comprising the extracellular matrix retard the
diffusion of antibiotics, making it harder for the antibiotics to reach the target site 53.
Moreover, the presence of polysaccharide matrix makes it difficult for the phagocytic
cells to engulf the biofilm cells 57. Besides these physical protections, the high level of
persister formation in nutrient-deficient environment of biofilms acts as a survival
strategy towards antibiotics or stress 7. As depicted in Figure 2.2, bacterial biofilm
development involves five stages: (i) reversible attachment of bacterial cells on the
surface, (ii) irreversible attachment by loss of flagellar motility and mediated by
exopolymeric substances, (iii) early development of biofilm architecture, (iv) maturation
by development of complex biofilm architecture, and (v) dispersal by release of motile
cells from the biofilm microcolonies 58. Besides flagella, P. aeruginosa also uses type IV
pili-mediated twitching motility and chaperone usher pathway (CUP) fimbriae in the
biofilm formation process 59,60.

Figure 2.2 Stages of bacterial biofilm formation on surfaces.
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The rate of bacterial attachment to a surface and biofilm formation are also
affected by the nutrient concentration and type, temperature, pH and ionic strength 61.
Novel approaches to control antibiotic resistant biofilms include: (i) small molecules that
interfere with biofilm formation, e.g. D-amino acids on S. aureus and P. aeruginosa
biofilms 62, chelators on S. aureus biofilms 63, N-acetylcysteine on S. epidermidis
biofilms 64, (ii) enzymes to degrade biofilm matrix, e.g. DNase I, Proteinase K and
trypsin on S. aureus biofilms 65,66, dispersin B on S. epidermidis biofilms 67, and (iii)
surface modification to inhibit biofilm formation, e.g. bactericidal/bacteriostatic coating
agents (silver, furanones) 68,69, anti-adhesion coating agents (silica colloids,
trimethylsilane plasma) 70,71. Due to high tendency of bacteria to form biofilm under
unfavorable conditions, in addition to their resilience towards antibiotics and host
immune systems, biofilms pose challenges to the control of bacterial infections.

2.3 Pseudomonas aeruginosa
P. aeruginosa is an opportunistic Gram-negative bacterial pathogen, that mainly affects
humans with compromised immune systems

72

. It is a metabolically versatile bacterium

and is known to cause a wide range of severe infections

73

. These infections include

urinary tract infections, bacteremia, bone and joint infections, respiratory system
infections, dermatitis, pneumonia, meningitis, endophthalmitis, endocarditis, septicemia,
and malignant external otitis

74-77

. Due to significant damage to host tissues, intrinsic

antibiotic resistance, and tendency to form biofilms, eradication of P. aeruginosa
infection is difficult

73,78,79

. In addition, the multiple virulence factors of P. aeruginosa

counteract the host immune defenses and increase the bacterium’s competitiveness in
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mixed microbial populations

73,80

. The environmental conditions and the status of host

immune system dictate the severity of P. aeruginosa infections, which can involve inert
colonization, chronic infections, or highly virulent acute infections 78,81.
The cell-associated virulence factors like pili, fimbriae, and flagella aid in
bacterial adherence to epithelial cells, motility, and invasion 82. In addition, the presence
of outermembrane non-pilus adhesins provides strong binding properties to P. aeruginosa
83,84

. Another virulence factor is lipopolysaccharide, a glycolipid and an endotoxin, which

forms the major portion of the outermost membrane of P. aeruginosa and acts as strong
stimulator of host innate immune responses 85,86. Under stress conditions, P. aeruginosa
converts to a mucoid phenotype, characterized by overproduction of exoploysaccharide
alginate, which behaves as a virulence factor by forming a protective layer around the
bacteria thereby combating high antibiotic concentrations and heightened immune
responses 87,88. Apart from the cell-associated virulence factors, P. aeruginosa tends to
produce extracellular virulence factors including toxins, proteases, hemolysins, and
enzymes 80,89. Figure 2.3 and Table 2.3 show the multidimensional P. aeruginosa
virulence factors that determine the pathogenicity of the bacterium and are responsible
for causing severe damage to the host.
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Figure 2.3 Schematic diagram of multiple virulence factors exhibited by
Pseudomonas aeruginosa.

Table 2.3 Extracellular virulence factors produced by Pseudomonas aeruginosa.
Virulence factor

Functions

Exotoxin A

Inhibits host protein synthesis, causes tissue damage and
immunosuppression 90.

Exoenzyme S

Mitogenic for T lymphocytes and induces T cell apoptosis
91
.

Elastase B

Degrades host elastin and collagen found in organs and
tissues 92.

Elastase A

Enhances the virulence activity of elastase B and host
elastolytic proteases like human leukocyte elastase and
human neutrophil elastase 93.

Protease IV

Degrades biologically important host proteins such as
fibrinogen, plasminogen, and immunoglobulin G (IgG) 94.
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Alkaline protease

Degrades laminin, a tissue-associated basement membrane
protein and causes hemorrhagic host tissue necrosis 95.

Hemolytic
phospholipase C

Causes intravascular hemolysis, organ damage, capillary
injury, myonecrosis, and allows bacterial escape from
intracellular phagolysosomes 96.

Pyocyanin

Interferes with vital host functions like cellular respiration,
electron transport, and cell-cycle regulation along with
maintaining dominance of P. aeruginosa with its
antimicrobial properties 97.

Leukocidin

Damages leukocytes and host tissues 98.

In patients suffering from cystic fibrosis (CF), P. aeruginosa converts to the
mucoid phenotype influenced by the CF microenvironment, and by overexposure to
antibiotics 99. Cystic Fibrosis is a severe autosomal recessive disease and is caused by
homozygous mutations in the CFTR (The Cystic Fibrosis Transmembrane Conductance
Regulator) gene, which is involved in transport of negatively charged chloride ions in and
out of cells 100,101. Water content is regulated by the transport of chloride ions to produce
thin, free flowing mucus 102. This mucus acts as a protective coating in the lungs,
digestive system, and reproductive system. 103 . The CFTR gene is also responsible for
the transport of positively charged sodium ions across cell membrane 101. Mutations in
the CFTR gene lead to overproduction of mucus in the tissues involving the respiratory
system, digestive system, reproductive system, and other organs 101. The defects in Na+
transport and the failure to secrete Cl- cause abnormal ion transport in CF airway
epithelia, leading to depleted airway surface liquid (ASL) volume and persistent mucin
secretions 104.
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The abnormal hyperproduction of viscid mucus observed in the lungs of CF
patients augment the risk of bacterial infections 105. For example, Staphylococcus aureus
and Hemophilus influenzae are most commonly found in the first decade of life of CF
patients, while in the second and third decade, Pseudomonas aeruginosa is the most
commonly found infectious agent, infecting around 80% of CF patients 105-107. In CF
patients, once P. aeruginosa forms biofilms, it is extremely difficult to eradicate 108. The
mucoid matrix provides increased protection to biofilms and contains a large quantity of
alginate exopolysaccharide 109. Fick et al. 110 found that about 85% of P. aeruginosa
strains isolated from the lungs of advanced stage CF patients had a mucoid morphology.

Figure 2.4 Differences between normal and cystic fibrosis lung airway.

Alginate is an O-acetylated linear polymer of D-mannuronate and L-guluronate
residues, that provides altered biofilm architecture for enhanced attachment to surfaces
and higher resistance towards antimicrobial treatments 88,111. The current
recommendations for eradication of P. aeruginosa in respiratory secretions include (i)
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intravenous anti-pseudomonal antibiotics, (ii) a regimen of nebulized colistin and oral
ciprofloxacin, and (iii) tobramycin solution for inhalation (TSI) 112-114. Nebulized
aztreonam lysine has been recently shown as a safe treatment for repeated use to suppress
chronic P. aeruginosa infections in the lungs of CF patients 115. Azithromycin, a
macrolide antibiotic, is regularly used as a treatment of chronic P. aeruginosa infections,
and has been shown to reduce exacerbations in the lungs of CF patients 116,117. Recently,
it was demonstrated that intranasally administrated bacteriophages (PAK-P3 and P3CHA) were effective in treating lung infections caused by P. aeruginosa strains 118.
Moreover, use of fosfomycin/tobramycin for inhalation (FTI) treatment was introduced
as a promising combination antipseudomonal therapy for patients with CF 119. Among the
treatments being tested for effective reduction of P. aeruginosa infections in CF patients,
alternating and combination antibiotic therapies, and new drug delivery options, are being
extensively studied for trials 104. In spite of the ongoing efforts, the limitations to
antibiotic dosage, host cell cytotoxicity, and ability of the bacterium to build up
resistance, require novel methods to eradicate chronic infections.

2.4 Immune System
During bacterial infection, the human immune system coordinates many types of cells
and molecules to eliminate the invading pathogen 120. Host innate immunity acts as the
first line of defense to block the entry of pathogens and to kill the microbes that
successfully penetrate the epithelial barrier 120. The innate immune system also activates
adaptive immunity, which is more specific against the invading microbe and provides
long-term protection by developing antibodies and memory lymphocytes 120. During
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innate immune response, macrophages and dendritic cells secrete cytokines, which are
signaling proteins acting as mediators to attract more immune cells, such as phagocytes
121

. Figure 2.5 shows a schematic diagram of hematopoiesis of human immune system

depicting differentiation of stem cells into different types of leukocytes.

Figure 2.5 Leukocytes of human immune system.
Innate immune cells express pattern recognition receptors (PRRs) to identify
pathogen-associated molecular patterns (PAMPs), such as bacterial lipopolysaccharide
(LPS), flagellin, peptidoglycan, and lipoteichoic acid molecules, which are essential for
survival of the microorganisms 122. The recognition of pathogens is followed by their
elimination by phagocytosis, which involve uptake of pathogens in phagosomes, and
micropinocytosis, which involves uptake of macromolecules and extracellular fluid
121,123,124

. For example, P. aeruginosa is recognized by macrophages by PAMPs and

undergoes phagocytosis, while enterohemorrhagic E. coli produces Shiga toxin that enter
host cells via macropinoctyosis 125,126.
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Cytokines are broadly categorized into groups such as lymphokines,
chemokines, and interleukins, depending on the cell of secretion, functions, and targets of
action 127. Cytokines derived from monocytes, are called monokines, while lymphokines
are derived from lymphocytes 127. Based on their functions, cytokines can be classified
into subgroups, including interleukins, tumor necrosis factors, interferons, colony
simulating factors, transforming growth factors, and chemokines 128. These cytokines
have important functions in regulating the host responses to infections and inflammation
128

. The bacterial PAMPs, such as lipopolysaccharides (LPS) and flagellin, induce

secretion of cytokines, thus mediating immune response 129. Some of the major cytokines
secreted and actively involved in immune responses during pathogenic infections are
shown in Table 2.4.
Table 2.4 Some major cytokines secreted during pathogenic invasions.
Cytokines
Interferons:
Interferon-α
(IFN- α)

Size
(kDa)

Antiviral, antiparasitic,
antiproliferative 130,131.

Fibroblasts, epithelial cells 132.

Antiviral, antiproliferative,
induces nerve growth factor
production 132-134.

T-cells, natural killer (NK)
cells 135,136.

Immunomodulation,
antiviral, antiparasitic,
antiproliferative 135,136.

17

Monocytes/macrophages, Tcells, NK cells, neutrophils,
lymphocytes, mast cells 137,138.

Inflammatory responses
during pathogenic infections,
induces tumor cell line
apoptosis 137,138.

25

T-lymphocytes 139,140.

Induces lymphocyte
proliferation, induces
inflammatory responses
139,140
.

20

Interferon-γ
(IFN- γ)

20-25

Lymphotoxin-α
(LT- α, also
known as TNF- β)

Functions

Monocytes/ Macrophages,
lymphoblastoid cells,
Fibroblasts 130,131.

19-26

Interferon-β
(IFN- β)

Tumor Necrosis
Factors:
Tumor Necrosis
Factor-α (TNF- α)

Source Immune Cells

134

24

Colony Stimulating
Factors:
Granulocyte
ColonyStimulating
Factor (G-CSF)

20

Monocytes/macrophages,
neutrophils, fibroblasts,
endothelial cells, stromal cells
141,142
.

Stimulates proliferation and
differentiation of
hematopoietic progenitor
cells into neutrophils,
modulates neutrophil
functions 141,142.

Macrophage
ColonyStimulating
Factor (M-CSF)

70-90

Monocytes, granulocytes,
fibroblasts, endothelial cells
143,144
.

Stimulates proliferation and
differentiation of
hematopoietic progenitor
cells into macrophages,
stimulates phagocytic and
chemotactic activities of
macrophages 143,144.

Granulocyte
Macrophage
ColonyStimulating
Factor (GM-CSF)

14-35

Macrophages, T cells, mast
cells, NK cells, endothelial
cells, fibroblasts 141,142,145,146.

Stimulates stem cells to
produce granulocytes and
macrophages, enhances
antimicrobial activity,
oxidative metabolism, and
phagocytic activity of
neutrophils and macrophages
141,142,145,146
.

17

Monocytes/macrophages,
neutrophils, endothelial cells,
fibroblasts, keratinocytes
147,148
.

Induces inflammatory
response during infections,
stimulates T-helper cells,
promotes proliferation of Bcells 142,143.

T-cells, B-cells, NK cells
.

Promotes proliferation of Tcells, anti-inflammatory
response to microbial
infections 144,145.

T-cells, keratinocytes, mast
cells, NK cells, endothelial
cells, monocytes 151.

Connects immune system
and hematopoietic system,
stimulates differentiation of
multipotent hematopoietic
stem cells into granulocytes,
macrophages, erthyroid cells,
megakaryocytes, mast cells
151
.

T-cells, mast cells 152,153.

Promotes proliferation of Tcells, induces antiinflammatory response to
infections, stimulates
activated B-cells 152,153.

Interleukins:
Interleukin-1
(IL-1)

Interleukin-2
(IL-2)

15.4

Interleukin-3
(IL-3)

15-17

Interleukin-4
(IL-4)

20

149,150

25

T-cells, mast cells 151,154.

Proliferation, cell activation,
differentiation of
eosinophils, promotes
generation of T-cells,
stimulates activity of B-cells
and increases immunoglobin
secretion during infections
146,149
.

Monocytes/macrophages, Tcells, fibroblasts, endothelial
cells 155-157.

Induces inflammatory
response during infections,
supports B-cells growth 155157
.

17.4

Bone marrow stromal cells
and thymic cells,
keratinocytes 158,159.

Induces proliferation during
maturation of B-cells, Tcells, magakaryocytes 158,159.

Interleukin-8
(IL-8)

8

Monocytes/macrophages,
endothelial cells, epithelial
cells 157,160.

Neutrophil chemotactic
factor, induces phagocytosis
157,160
.

Interleukin-10
(IL-10)

19

Monocytes, T-cells 161-163.

Induces anti-inflammatory
response during infections,
enhances B-cell survival and
proliferation, inhibits
synthesis of proinflammatory
cytokines 161-163.

Interleukin-11
(IL-11)

23

Bone marrow stromal cells,
mesenchymal cells 164,165.

Stimulates lymphocytes
growth, modulates antigenantibody responses 164,165.

Interleukin-12
(IL-12)

70

Dendritic cells, macrophages,
lymphocytes 166,167.

Stimulates growth and
function of T-cells, enhances
cytotoxic activity of NK
cells 166,167.

5-8

Macrophages, pituitary cells,
keratinocytes, hepatocytes,
platelets 168,169.

Multiple cell proliferation,
involved in tumerogeneis
promotes angiogeneis,
168,169
.

25

Macrophages, lymphocytes,
endothelial cells,
keratinocytes, leukemia cells
170-172
.

Induces proinflammatory
response, inhibits
proliferation of T-cells 170-172.

Interleukin-5
(IL-5)

50-60

Interleukin-6
(IL-6)

21.5-28

Interleukin-7
(IL-7)

Growth factors:
Transforming
Growth Factor-α
(TGF- α)
Transforming
Growth Factor-β
(TGF- β)

The table shows examples of major cytokines involved in immunological response during
pathogenic infections, and is not an all-inclusive list.
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2.4.1

Cytokine therapy

Cytokines play important roles in the regulation of cell proliferation, inflammation,
immunity, migration, fibrosis, repair, and angiogenesis 173. Cytokines are being explored
for therapeutic purposes, owing to their multiple actions on target cells at low
concentration ranges (e.g. picomolar and femtomolar) 174. Immune-based therapies
(IBTs) are designed to improve the immune system and approved cytokine therapies are
being used, while clinical trials are being carried out for some cytokine therapies. For
example, IFN-α is used against hepatitis B & C, leukemia, malignant melanoma, and
Kaposi’s sarcoma (KS); IFN-β is used in multiple sclerosis; IFN-γ is used in chronic
granulomatous disease, osteoporosis, and cancer; IL-2 is used in renal cell carcinoma and
metastatic melanoma; IL-11 is used in post chemotherapy induced thrombocytopenia; GCSF is used to treat neutropenia and recovery of bone marrow; TNF- α is used in
therapeutics of Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, ankylosing
spondylitis 174.
Active research is being performed on anti-HIV therapy through cytokines and
their inhibitors besides clinical use of cytokine therapies 175. The findings from extensive
studies and clinical research being carried out on cytokine therapies indicate novel
unknown functions of cytokines, which have not been thought of previously. Cytokine
pleiotropy and redundancy suggest that cytokine have multiple actions, and difference
cytokines can display similar functions 176. Studying every cytokine individually and
exploring its functions can give answers and solutions to health issues we have been
struggling to find effective cures for. The complex role of cytokines during bacterial
pathogenesis needs to be studied and understood further. There have been several studies,
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which show that bacterial attachment to epithelial cells induce the release of cytokines
177-179

. Porat et al. 180 showed that IL-β, IL-2, GM-CSF, and epidermal growth factor

(EGF) bind to virulent strains, and also stimulate their growth. Denis et al. 181 were able
to enhance the growth of a virulent strain of E. coli by IL-2 and GM-CSF. However, to
our knowledge, there haven’t been studies showing a direct connection between bacterial
persistence and host cytokines, and the effect of cytokines on bacterial persistence has yet
to be explored.

2.4.2 Granulocyte Macrophage Colony-Stimulating Factor
Granulocyte macrophage colony-stimulating factor (GM-CSF) is considered as the
central regulator of innate immune response and is previously found to reactivate the
impaired immune responses in immunocompromised mice or human cells 182-184. Burgess
et al.185 first identified granulocyte macrophage colony-stimulating factor (GM-CSF) in
the mouse, by its ability to stimulate the proliferation of mouse bone marrow cells in
vitro, and to generate colonies of granulocytes and macrophages. GM-CSF is secreted by
macrophages in response to microbial infections, and plays important roles in the survival
and activation of macrophages, neutrophils, eosinophils, and the maturation of dendritic
cells (Figure 2.6) 186. Human GM-CSF contains 127 amino acids, with four cysteine
residues, two glycosylation sites; its calculated molecular weight (MW) is 14 kDa 187.
The receptor for GM-CSF is CD116, which is expressed on the hematopoietic cells, and
is composed of a α chain and β chain 188,189. GM-CSF binds to the α chain of CD116 with
low affinity, but its binding to the β chain causes dimerization of both α and β subunits
188,189

. This dimerization increases the binding affinity of GM-CSF to its receptor, leading
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to receptor activation and subsequent stimulation of the JAK2 (Janus Kinase 2) signaling
pathway 188-190, which controls the production of blood cells from hematopoietic stem
cells 190. Increase in the serum level of GM-CSF helps recruit monocytes/macrophages to
sites of infection 191. Under normal conditions, the level of human GM-CSF in the
circulation is below 0.35 pM, but it increases in response to P. aeruginosa
lipopolysaccharide (LPS), a major component of the outer membrane of this microbe.
86,192

.

Figure 2.6 GM-CSF pathway in the immune system.

Compared to the well documented studies on cytokine production and the
functions of cytokines in stimulating host immune cells, little is known about the direct
effects of these immune factors on bacteria. The mechanisms of such phenomenon are
not well understood and, to our knowledge, effects of cytokines on antibiotic tolerant
persister cells have not been explored. Kanangat et al. 193 studied intracellular growth of
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S. aureus, P. aeruginosa, and Acinetobacter sp. (6 × 106 CFU of each strain) added to
monocytic cells primed with low doses (0, 10, 100, and 250 pg) and high doses (1 and 10
ng) of IL-1 β, IL-6, and TNF-α. It was found that at low cytokine doses (10 to 250 pg),
the intracellular bacterial growth of all strains decreased; however, as the dose increased
to 10 ng, the trend reversed 193. It was speculated that above the threshold of host cellular
activation, the conditions become favorable for survival and replication of the ingested
bacteria 193.

2.4.3

Clinical Significance and Uses of GM-CSF

A major clinical application of GM-CSF is the treatment of neutropenia following
chemotherapy, which is often characterized by an abnormally low number of neutrophils,
leading to weakening of primary defense against infections by pathogenic
microorganisms 194. GM-CSF treatment leads to a significant increase in the total white
blood cell count (TWBC), and absolute neutrophil count (ANC) 194. GM-CSF is also
known to cause faster neutrophil recovery in patients receiving autologous bone marrow
transplantation 195. Besides shortening the period of absolute neutropenia, the use of GMCSF also led in one study to fewer infections, lowered antibiotic usage, and shorter
duration of hospitalization 195. Moreover, Ye et al. 196 constructed a cytokine fusion
protein consisting of GM-CSF and monocyte chemotactic activating factor (MCAF),
which was able to sustain the growth of GM-CSF-dependent cell line, TF1 (a human
premyeloid cell line which proliferates in response to cytokines) and TF1 cells were
chemotactic for monocytes. The presence of fusion protein inhibited growth of several
human tumor cell lines and mediated recruitment of monocytes to the tumor site 196. GM-
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CSF was also shown to suppress leukemic cell apoptosis induced by Vp16, a cytotoxic
anticancer drug 197.
Some animal studies indicate that GM-CSF modulates lipid peroxidation and
glutathione (GSH) content of the skin wound, thus reducing the lethal irradiation effects
on incisional healing and production of cell damaging oxygen radicals 198. Cytotoxic
drug tolerance is enhanced by GM-CSF, permitting drug dose maintenance or increase in
desired drug effects. For example, combination therapy with GM-CSF and tiazofurin
shows led to a decrease in GTP pools caused by tiazofurin in vitro, and was beneficial for
refractory leukemia patients 199. The use of immunotherapeutic agents is being explored
for the treatment of drug resistant Tuberculosis (TB) caused by Mycobacterium
tuberculosis 200. Nambiar et al. 201 demonstrated that target delivery of GM-CSF to the
lungs of immunodeficient mice through the GM-CSF-secreting Mycobacterium bovis
BCG vaccine strain (BCG:GM-CSF) led to an increase in pulmonary dendritic cell
numbers and 10-fold more efficient clearance of Mycobacterium tuberculosis H37Rv.
Fleischmann et al. 202 demonstrated that 90% of polymorphonuclear neutrophils from
humans turned phagocytic after exposure to 100 pM GM-CSF for 2 h. These studies
suggest that GM-CSF is actively involved in immune response to pathogenic invasion.
In summary, GM-CSF has good therapeutic potential, as demonstrated for its
antitumor activities, functions in reconstitution of hematopoietic system, increase in
cytotoxic drug tolerance, reduction in infections by pathogens, and enhanced efficacy of
antibiotics. More extensive studies on the dosage of GM-CSF, its possible roles
depending on the presence or absence of other cytokines, and overall context of the
immune response need to be performed to establish a reliable GM-CSF based therapy.
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CHAPTER 3

SYNERGY BETWEEN GRANULOCYTE MACROPHAGE
COLONY- STIMULATING FACTOR (GM-CSF) AND
ANTIBIOTICS PROMOTE THE KILLING OF PERSISTER CELLS
OF PSEUDOMONAS AERUGINOSA
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3.1 Abstract
Bacterial persister cells are highly tolerant to antibiotics and play important roles in
chronic infections. However, the effects of host immune factors on persister cells have
not been studied. To bridge this knowledge gap, we investigated the effects of
granulocyte macrophage-colony stimulating factor (GM-CSF), a human cytokine, on the
viability and persistence of the wild-type strain Pseudomonas aeruginosa PAO1, its
mucoid mutant P. aeruginosa PDO300, and the non-pathogenic Escherichia coli K12.
GM-CSF was found to sensitize the persister cells of P. aeruginosa PAO1 and PDO300
to multiple antibiotics including ciprofloxacin, tobramycin, tetracycline, and gentamicin.
For example, after treatment with 0.17 pM GM-CSF for 1 h, 96.2±5.9% and 79.3 ± 8.3%
of persister cells of two different strains of P. aeruginosa PAO1 from exponential phase
cultures were rendered sensitive to 200 µg/mL ciprofloxacin. Significant effects were
also observed for the mucoid strain P. aeruginosa PDO300, but not for the nonpathogenic E. coli K12. In comparison, no such effect was found against the normal cells
of P. aeruginosa PAO1, PDO300, and E. coli K12. GM-CSF was found to significantly
sensitize the biofilm cells of P. aeruginosa PAO1 and PDO300 to tobramycin in the
presence of biofilm degrading enzymes like DNase I and alginate lyase respectively.
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3.2 Introduction
Bacterial populations commonly harbor a phenotypically distinct and dormant
subpopulation of persister cells which possess high level antibiotic resistance 1. The
opportunistic pathogen Pseudomonas aeruginosa is a good model system for persister
research 2 . It is known to cause respiratory system infections, bone and joint infections,
urinary tract infections, dermatitis, gastrointestinal infections, etc. in patients with
weakened immune systems due to burn wounds, cystic fibrosis, organ transplants, AIDS,
and acute leukemia 2. In cystic fibrosis patients, P. aeruginosa causes chronic infections,
despite highly aggressive antimicrobial therapy 3-5. The ability of P. aeruginosa to attach
to surfaces and form biofilms with increased number of persister cells embedded in a
protective extracellular matrix makes the pathogen even more challenging to treat 6-8.
The antibiotics regularly used to treat P. aeruginosa include aminoglycosides
(protein synthesis inhibitors), β-lactams (cell wall synthesis inhibitors), fluoroquinolones
(nucleic acid synthesis inhibitors), and polymyxins (membrane disruptors) 9. Because
persisters are resistant to antibiotic treatments, it remains a challenge to eradicate this
dormant subpopulation using antibiotics which can only destroy normal cells 10,11. When
the treatment is stopped, the surviving persister cells revert to normal state and repopulate
by actively multiplying 12,13. Owing to the survival strategies displayed by pathogenic
bacteria through dormancy, antibiotic resistance, and biofilm formation, it is important to
develop innovative methods to address these challenges.
Cytokines are signaling proteins produced by the immune cells and play a critical
role in protection against bacterial and viral infections 14-16. We were motivated to
investigate the interactions between cytokines and bacteria. The pro-inflammatory
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cytokines such as IL-1 and TNF- α promote systematic inflammation 17,18. In contrast, the
anti-inflammatory cytokines such as IL-4, IL-10, and GM-CSF control the proinflammatory response and counteract the inflammation effects 19-21. Granulocyte
macrophage colony-stimulating factor (GM-CSF), a cytokine secreted by macrophages,
T-cells, mast cells, NK cells, endothelial cells, and fibroblasts is considered as a major
regulator governing the maturation of granulocytes and macrophages 22,23. GM-CSF also
plays a key role in inflammatory and autoimmune diseases 24-26. The significant roles of
GM-CSF during bacterial infections have been well documented 26-33.
However, the direct interaction of GM-CSF and bacterial persister cells has not
been explored. Thus, we selected GM-CSF as a representative cytokine to investigate its
effects on bacterial persister cells. We chose P. aeruginosa as the model bacterium
because it is a widely used organism for research on persister cells and biofilms 7,11,34-38.
Effects of GM-CSF on P. aeruginosa PAO1 and the mucoid strain PDO300 were
compared with GM-CSF introduced either alone, or with an antibiotic, to test synergy.
PDO300 is a mucA22 mutant (due to a single base pair deletion) of P. aeruginosa PAO1,
which overproduces the exopolysaccharide alginate 39. The alginate overproduction by
mucoid P. aeruginosa makes the biofilms thicker, which hinders the penetration of
antibiotics and reduces the phagocytic activity of macrophages 40. Alginate
overproduction also leads to mucoidity, which is commonly seen in late stage cystic
fibrosis patients with multidrug tolerant infections 41. The non-pathogenic laboratory
strain Escherichia. coli K12 was selected in this study to understand if GM-CSF has
different activities on pathogenic and non-pathogenic strains.
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3.3. Materials and Methods

3.3.1 Bacterial strains and growth media
The bacterial strains used in this study include two P. aeruginosa PAO1 strains (obtained
from Prof. Thomas. K Wood 42 at Pennsylvania State University and Prof. Matthew
Parsek 43 at University of Washington, respectively) an isogenic mucoid mutant PDO300
(mucA22), and E. coli K12. Overnight cultures of these strains were prepared in Luria
Bertani (LB) medium 44 containing 10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl
at 37ºC with shaking at 200 rpm. Recombinant human GM-CSF was purchased from
R&D systems (Minneapolis, MN, USA). The stocks used in this study contained 10
µg/mL GM-CSF, dissolved in phosphate buffer saline (PBS) pH 7.4, supplemented with
0.1% bovine serum albumin (BSA).

3.3.2 Effects of GM-CSF on planktonic cells
The experiments performed on the planktonic cells were conducted with cells harvested
from both the exponential and stationary phase (16 h after inoculation) cultures. For
stationary cultures, the cells from an overnight culture of in LB medium were collected
by centrifuging at 8,000 rpm for 10 min and washed twice with PBS (pH 7.4). The
washed cells were resuspended in 25 mL PBS buffer and vortexed gently for 1 min to
separate cells. A portion of the sample was used to determine the viability by plating the
cells on LB agar plates and counting CFU using the drop plate method, as described
previously 45, while the remainder was used for isolation of persisters by adding 200
µg/mL ciprofloxacin for P. aeruginosa PAO1 and PDO300, and 100 µg/mL ampicillin
for E. coli K12, and incubating at 37ºC for 3.5 h with shaking at 200 rpm 11,46. After
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incubation, the antibiotic was washed away with PBS buffer by centrifuging thrice at 4ºC,
8,000 rpm for 10 min each, and vortexed for 1 min after adding PBS. To test the effects
of GM-CSF on viability of persister cells, the washed cells were transferred to
microcentrifuge tubes, with 1 mL of washed cells in each tube. GM-CSF was added at 0,
0.17, 1.7, and 17 pM. These concentrations were selected because 0.17 pM is the
concentration of GM-CSF found in the blood plasma of healthy humans 47. The amount
of BSA (0.1%) was adjusted to be the same for all samples so that the effects of GM-CSF
can be studied specifically.
For exponential phase planktonic cells, the experiments were performed with
cells harvested from exponential phase subcultures with an optical density at 600 nm
(OD600) of 0.3 to 0.4. After preparing an overnight culture of the tested strain in 25 ml LB
medium, a subculture in LB medium was inoculated to an OD600 of 0.01. The subculture
was incubated at 37ºC with shaking at 200 rpm for 3-4 h, until the OD600 reached 0.3 to
0.4. After washing the subculture twice by centrifuging at 8,000 rpm for 10 min with PBS
(pH 7.4) and isolating persister cells as described above, sequential treatment was
performed for 1 h with 0.17 pM GM-CSF, followed by an antibiotic for 3.5 h. The
viability of both normal and persister populations were quantified after treatments for 1 h
and 3.5 h using drop plate method as described above. The antibiotics (ciprofloxacin,
tobramycin, tetracycline, and gentamicin) used for exponential phase cultures were added
at a concentration of 200 µg/mL for both P. aeruginosa PAO1 and PDO300. To confirm
that any change in the viability of bacterial cells is due to the specific effect of GM-CSF
rather than any contaminant, the persister cells of P. aeruginosa PAO1 isolated from
exponential phase cultures were treated with 0.17 pM GM-CSF in the presence of
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different concentrations of anti-GM-CSF antibody (0, 17, and 170 pM). The persister
cells underwent treatment with GM-CSF alone, anti-GM-CSF alone, or GM-CSF
neutralized by anti-GM-CSF for 2 h. Five µg/mL ciprofloxacin was then added to all
samples, which were incubated for 3.5 h. After washing the cells thrice at 13,200 rpm for
2 min, CFU was counted using drop plate method.

3.3.3 Effect of GM-CSF on biofilm cells
After preparing an overnight culture, each bacterial strain tested for biofilm formation
was subcultured to an initial OD600 of 0.01 in a petri dish containing 20 mL LB medium
and sterile 316L stainless steel coupons (1.75 cm x 1 cm, 0.05 cm thick). The biofilms of
P. aeruginosa PAO1 and PDO300 were grown for 24 h at 37ºC without shaking. After
incubation, the coupons were washed by gently dipping in PBS and placed in 12-well
plates. There were 7 treatment conditions in total and each condition was tested in
triplicate: (i) GM-CSF alone, (ii) antibiotic alone, (iii) GM-CSF and alginate lyase, (iv)
GM-CSF and antibiotic, (vi) antibiotic and alginate lyase, and (vii) GM-CSF, antibiotic,
and alginate lyase. In all the experiments, the concentrations of GM-CSF and alginate
lyase were kept at 0.17 pM and 50 µg/mL, respectively. The control samples were
supplemented with the same amount of BSA (0.1%) as present in the samples with 0.17
pM GM-CSF. The coupons were incubated at 37ºC for 3.5 h. After treatment, each
coupon was gently washed with PBS and placed in a test tube containing 3 mL of PBS.
The coupons were gently sonicated (B200, Sinosonic Industrial Co., Ltd., Taiwan) for 4
min to release biofilm cells from coupon surface. This condition was confirmed to not
kill the cells 48. After vortexing for 1 min, the cell suspensions were plated on LB agar
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plates using drop plate method to count the number of CFU after incubation at 37ºC for
24 h as described previously 45. Similar tests were performed on early (4 h) biofilm cells
of P. aeruginosa PAO1 by using 5 units/mL DNase I instead of alginate lyase, and a
lower concentration of 20 µg/mL tobramycin was used as the early stage biofilms have a
significantly smaller bacterial population. To find if alginate lyase and DNase I have any
cidal effects on the biofilm cells, alginate lyase at concentrations 10, 50, 100, and 200
µg/mL were tested on 24 h biofilms of P. aeruginosa PAO1 and PDO300, while DNase I
at 1, 2, 5, and 10 units/mL were tested on 4 h biofilms of P. aeruginosa PAO1.

3.3.4 Effect of alginate lyase on GM-CSF diffusion across alginate layer
Polysaccharide alginate layers were developed on transwell inserts (0.4 μm pore size) by
adding 100 μL of 0.3% w/v alginate (Sigma-Aldrich, St. Louis, MO, USA) in deionized
water to each well. The transwell inserts were kept in a desiccator for 15 min under
vacuum to remove water, followed by addition of 50 ng of GM-CSF (R&D systems,
Minneapolis, MN) in 100 μL deionized water to each well. For the treatment samples,
100 μg/mL alginate lyase (in 100 μL deionized water) was added along with GM-CSF.
Then the transwells were transferred to a 12-well plate with 1 mL deionized water in each
well to submerge the transwell insert. GM-CSF was allowed to diffuse at 37ºC over 2 h.
The samples (10 μL each) were taken from transwell insert (labeled as “top”) and the
well underneath the transwell (labeled as “bottom”) at 0, 1, and 2 h to determine the
amount of GM-CSF using Western blotting.
For Western blotting, the protein samples were first separated with
electrophoresis using 10% acrylamide gels. As a positive control, 50 ng GM-CSF was
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loaded. After electrophoresis, the gels were transferred to blotting chambers for Western
blotting (to PVDF transfer membranes at 250 mA for 2 h) and GM-CSF was detected
using mouse-derived anti-GM-CSF (1:2000 dilution) as the primary antibody and antimouse IgG conjugated with alkaline phosphatase (1:20,000 dilution) as the secondary
antibody. BCIP (5-bromo-4-chloro-3-indolyl-phosphate) and NBT (nitro blue
tetrazolium) were used (30 min of incubation with the membranes) to detect the alkaline
phosphatase activity of conjugated secondary antibody. This experiment was conducted
in triplicate and consistent results were obtained.

3.3.5 Kinetics of bacterial killing during antibiotic treatment
The antibiotic conditions used for isolation of persister cells of P. aeruginosa PAO1 ,
PDO300, and E. coli K12 were confirmed by measuring the killing curves over time
similar to method described previously 49,50. The cells were harvested from exponential
and stationary cultures, and treated with 200 µg/mL ciprofloxacin (P. aeruginosa PAO1
and PDO300) or 100 µg/mL ampicillin (E. coli K12) for 4.5 h. CFU during treatment was
determined from samples at every 0.5 h after antibiotic treatment.

3.3.6 Statistical Analyses
The CFU data were analyzed with one-way ANOVA followed by Tukey test using SAS
9.2 software (SAS Institute, Cary, NC, USA). The results with p < 0.05 are considered
significant.
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3.4 Results

3.4.1 Identifying the appropriate antibiotic concentrations for persister isolation
The multidrug tolerant persister cells differ from antibiotic resistant mutants 49,50.
Antibiotic resistant mutants are based on acquired genes and have the ability to grow in
the presence of antibiotics, while multidrug tolerance is a reversible physiological state
without a genetic basis 51,52. This latter characteristic enables the subpopulation of
persisters to survive killing by antibiotics, and to resume growth when antibiotics are
removed, thus reverting to normal physiological stage of antibiotic sensitivity 51,52. The
presence of the persister population was confirmed for the planktonic cells of P.
aeruginosa PAO1, PD300 and E. coli at exponential and stationary phases, as shown in
Figure 3.1. It was observed that the 3.5 h treatment with high concentration of antibiotics
(200 µg/mL ciprofloxacin for P. aeruginosa PAO1 and PDO300; 100 µg/mL Ampicillin
for E. coli 12) resulted in a small group cells that did not respond to the increase in
antibiotic treatment duration. Such a biphasic killing curve is a signature of cultures
harboring persister cells, which proved that the conditions are effective in isolating
persisters.
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Figure 3.1 Antibiotic conditions used for the isolation of persister cells provide drugtolerant bacterial population in both exponential and stationary phase cultures.
Antibiotic conditions used for the isolation of persister cells from cultures at exponential
phase for (A) P. aeruginosa PAO1 (200 µg/mL ciprofloxacin for 3.5 h), (B) P.
aeruginosa PDO300 (200 µg/mL ciprofloxacin for 3.5 h), and (C) E.coli K12 (100
µg/mL ampicillin for 3.5 h), cause biphasic kill curves with a significant decline in
killing rate and a dominant drug-tolerant population. Similar biphasic kill curves were
observed for antibiotic conditions used for the isolation of persister cells from the
cultures at stationary phase for (D) P. aeruginosa PAO1 (200 µg/mL ciprofloxacin for
3.5 h), (E) P. aeruginosa PDO300 (200 µg/mL ciprofloxacin for 3.5 h), and (F) E.coli
K12 (100 µg/mL ampicillin for 3.5 h). Cip: ciprofloxacin. Amp: Ampicillin. The samples
were tested in triplicate (n=3). Error bars represent SD.
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3.4.2 GM-CSF sensitized the planktonic persister cells of P. aeruginosa PAO1 to
antibiotics
We started this study using the P. aeruginosa PAO1 strain 42 obtained from Prof.
Thomas K. Wood at Penn State University. Treatment with 0.17 pM GM-CSF alone did
not affect the viability of persister cells isolated (by treatment with 200 µg/mL
ciprofloxacin for 3.5 h) from the exponential cultures (p=0.36; One-way ANOVA
followed by Tukey test (when needed) used throughout this study) (Figure 3.2A).
However, the treatment with GM-CSF significantly sensitized the persister cells to
antibiotics. For example, treatment with 0.17 pM recombinant human GM-CSF
(henceforth GM-CSF) for 1 h sensitized 96.2±5.9% (p = 0.0002), 91.3±1.2% (p <
0.0001), 61.4±16.6% (p = 0.0119), and 47.6±14.9% (p = 0.0030) of persister cells to 200
µg/mL of ciprofloxacin, tobramycin, tetracycline, and gentamicin respectively; while
these antibiotics alone were found ineffective in killing persister cells (p > 0.05) (Figure
3.2A). To test if GM-CSF is also effective against the mucoid strain of P. aeruginosa, we
also tested another wild-type strain of P. aeruginosa PAO1 43 obtained from Prof.
Matthew Parsek at the University of Washington, so that the isogenic mucoid strain P.
aeruginosa PDO300 43 can be compared. Similar results were obtained for the PAO1
strain from Parsek lab; e.g., treatment with 0.17 pM GM-CSF alone did not affect the
viability of persister cells isolated from exponential cultures (p = 0.37) (Figure 3.2B), but
sensitized the persister cells to antibiotics. For example, treatment with 0.17 pM GMCSF for 1 h sensitized 79.3±8.3% (p = 0.0002), 72.2±12.7% (p = 0.0012), and 45.7±7.8%
(p = 0.001) of persister cells to 200 µg/mL of ciprofloxacin, tobramycin, and tetracycline,
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respectively (Figure 3.2B). Treatment with any of these antibiotics alone did not cause
significant killing of persister cells (p > 0.05 for all).

Figure 3.2 GM-CSF sensitized the persister cells of P. aeruginosa PAO1 isolated
from exponential phase cultures to antibiotics. The wild-type PAO1 obtained from two
different sources were tested including one (A) from Prof. Thomas K. Wood at
Pennsylvania State University and another (B) from Prof. Matthew Parsek at University
of Washington. The persister cells were isolated from exponential phase cultures by
killing the normal cells with 200 μg/mL ciprofloxacin for 3.5 h, and then treated with
0.17 pM GM-CSF alone for 1 h, followed by additional treatment with GM-CSF plus an
antibiotic as indicated for 3.5 h (all tested at 200 μg/mL). Following the treatment, the
viability of persister cells was determined by counting CFU. Cip: ciprofloxacin. Tob:
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tobramycin. Tet: tetracycline. Gen: gentamicin. The samples were tested in triplicate
(n=3). Error bars represent SD; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001,
one-way ANOVA followed by Tukey test.

Since the results were consistent with the other PAO1 strain and an isogenic
mucoid strain is available, the PAO1 strain from the Parsek lab (henceforth PAO1) was
used for the rest of this study. Moreover, since the persister population is higher in
stationary phase, we also tested if GM-CSF is effective against persister cells isolated
from stationary phase cultures. The concentrations of antibiotics were also reduced to
understand if GM-CSF can sensitize the persister cells to antibiotics at lower
concentrations. GM-CSF did not significantly affect the viability of persisters in the
absence of an antibiotic (0.17, 1.7, and 17 pM GM-CSF tested; p > 0.3 for all conditions),
and synergistic effects were observed between GM-CSF and antibiotics in killing PAO1
persister cells isolated from stationary phase cultures. Specifically, treatment with 0.17
pM GM-CSF sensitized 61.5±14.5% (p = 0.0003) and 77.1±2.0% (p = 0.0048) of
persister cells to 5 µg/mL ciprofloxacin, and 5 µg/mL tobramycin, respectively (Figure
3.3A and B). At a higher concentration of 17 pM, GM-CSF sensitized 74.0±2.9% (p =
0.0005) and 86.5±1.7% (p = 0.0002) of persister cells to 5 µg/mL ciprofloxacin and 5
µg/mL tobramycin, respectively (Figure 3.3A and B).
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Figure 3.3 GM-CSF sensitized the persister cells of P. aeruginosa PAO1 isolated
from stationary phase cultures to antibiotics. The persister cells were isolated from
stationary phase cultures by killing the normal cells with 200 μg/mL ciprofloxacin for 3.5
h, and then treated with GM-CSF plus (A) 5 μg/mL ciprofloxacin, and (B) 5 μg/mL
tobramycin. Following the treatment, the viability of persister cells was determined by
counting CFU. Cip: ciprofloxacin. Tob: tobramycin. The samples were tested in
triplicate (n=3). Error bars represent SD; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p <
0.0001, one-way ANOVA followed by Tukey test.
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To confirm that the observed effects were caused by GM-CSF, rather than
contaminant in the sample, we also tested the effects in the presence of anti-GM-CSF. As
shown in Figure 3.4, addition of anti-GM-CSF abolished the effects of GM-CSF. Thus,
the observed effects on persister cells were indeed caused by GM-CSF.

Figure 3.4 Effect of 0.17 pM GM-CSF on P. aeruginosa PAO1 persister cells was
abolished by anti-GM-CSF. The persister cells were isolated from exponential phase
cultures. All samples underwent the same incubation duration. The figure shows the
viability of persister cells treated with GM-CSF alone, anti-GM-CSF alone, or GM-CSF
neutralized by anti-GM-CSF (2 h incubation) followed by 5 µg/mL ciprofloxacin for 3.5
h. The amount of BSA (0.1%) was adjusted to be the same for all samples. Following the
treatment, the viability of persister cells was determined by counting CFU. The samples
were tested in triplicate (n=3). Error bars represent SD; * p < 0.05, ** p < 0.01, *** p <
0.001, **** p < 0.0001, one-way ANOVA followed by Tukey test.
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3.4.3 GM-CSF is effective against the mucoid strain P. aeruginosa PDO300 in the
presence of alginate lyase
To understand if GM-CSF also affects the mucoid strains of P. aeruginosa, the persister
cells of P. aeruginosa PDO300 (henceforth PDO300) isolated from exponential cultures
were tested following the same protocol. Similar to the results of the wild-type PAO1,
treatment with 0.17 pM GM-CSF did not change the viability of PDO300 persister cells
(p = 0.77), but sensitized 40.5±18.6% (p = 0.04) persister cells to 200 µg/mL tetracycline.
The decrease in activities of GM-CSF against PDO300 persister cells is probably due to
the presence of its alginate layer since when 50 µg/mL alginate lyase was added, the
killing by 200 µg/mL tobramycin and 0.17 pM GM-CSF increased to 66.9±12.4% (p =
0.0002) (Figure 3.5).
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Figure 3.5 Alginate lyase is required for the activity of GM-CSF against persister
cells of the mucoid strain P. aeruginosa PDO300. The persister cells were isolated
from exponential phase cultures and GM-CSF was tested at 0.17 pM. The viability of
persister cells treated with tobramycin (200 μg/mL) alone, tobramycin along with
alginate lyase (50 µg/mL), or tobramycin along with alginate lyase and GM-CSF is
shown. The amount of BSA (0.1%) was adjusted to be the same for all samples.
Following the treatment, the viability of persister cells was determined by counting CFU.
Tob: tobramycin. AL: alginate lyase. The samples were tested in triplicate (n=3). Error
bars represent SD; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, one-way
ANOVA followed by Tukey test.

3.4.4 GM-CSF enhanced the killing of biofilm cells
To understand if GM-CSF is also effective against P. aeruginosa biofilm cells, the 24 h
biofilm cells of PAO1 and PDO300 were treated with GM-CSF in the presence and
absence of antibiotics. Treatment with 0.17 pM GM-CSF alone did not change the
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viability of biofilm cells of either strain. We hypothesized that the presence of biofilm
matrix may block or retard the penetration of GM-CSF. Alginate lyase at different
concentrations (10, 50, 100, and 200 µg/mL) was tested on P. aeruginosa PAO1 and
PDO300 biofilms, but alginate lyase had insignificant effect (p > 0.05) on the biofilm
cells. To test if GM-CSF is more effective if the biofilm matrix is degraded, alginate
lyase was added at 50 µg/mL in addition to 200 µg/mL tobramycin and 0.17 pM GMCSF. GM-CSF and alginate lyase did not kill biofilm cells significantly in the absence of
antibiotic for both strains; however, co-treatment with 50 µg/mL alginate lyase, 0.17 pM
GM-CSF, and 200 µg/mL tobramycin killed the PDO300 biofilm cells by 97.2±0.4% (p
= 0.0002), corresponding to 61.3±6.0% (p = 0.03) more killing than treatment with
tobramycin alone and 57.1±6.6% (p = 0.07) more killing compared to tobramycin and
alginate lyase together (Figure 3.6). However, for P. aeruginosa PAO1 biofilm cells,
addition of alginate lyase did not exhibit synergistic effects between GM-CSF and
antibiotics. For example, addition of 0.17 pM GM-CSF and 0.05 mg/mL alginate lyase
did not further reduce the viability of biofilm cells compared to treatment with 200
µg/mL tobramycin alone (p = 0.82). This is probably because alginate is not a major
component of the extracellular polysaccharide matric of the wild-type P. aeruginosa
PAO1, as reported by Wozniak et al. 53.
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Figure 3.6 GM-CSF enhanced the killing of P. aeruginosa PDO300 biofilm cells by
tobramycin and alginate lyase. P. aeruginosa PDO300 cells in 24 h biofilms were
treated with (i) 0.17 pM GM-CSF alone, (ii) 200 μg/mL tobramycin alone, (iii) 0.17 pM
GM-CSF and 50 µg/mL alginate lyase, (iv) 200 μg/mL tobramycin and 50 μg/mL
alginate lyase, (v) 0.17 pM GM-CSF and 200 μg/mL tobramycin, and (vi) 0.17 pM GMCSF, 200 μg/mL tobramycin, and 50 μg/mL alginate lyase, for 3.5 h. The amount of BSA
(0.1%) was adjusted to be the same for all samples. Following the treatment, the viability
of persister cells was determined by counting CFU. Tob: tobramycin. AL: alginate lyase.
The samples were tested in triplicate (n=3). Error bars represent SD; * p < 0.05, ** p <
0.01, *** p < 0.001, **** p < 0.0001, one-way ANOVA followed by Tukey test.

The major components of PAO1 biofilms are (i) extracellular DNA which
mediates cell to cell interaction, (ii) Pel, a glucose-rich polymer which provides structural
scaffold at early stages of biofilm formation, and (iii) Psl, rich in mannose and galactose,
and is involved in initial attachment and biofilm maturation 54. Since early PAO1
biofilms are known to contain a large amount of DNA, we tested if addition of DNase I
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could increase the activity of GM-CSF in killing early stage (4 h) PAO1 biofilm cells.
DNase I was tested at different concentrations (1, 2, 5, and 10 units/mL) on early PAO1
biofilms and it was found that DNase I had insignificant effects (p > 0.05) on the viability
of biofilm cells. However, addition of DNase 1 along with GM-CSF and tobramycin was
found to kill P. aeruginosa PAO1 biofilm cells significantly. For example, when 5
units/mL DNase 1 and 0.17 pM GM-CSF were added along with 20 µg/mL tobramycin
(lower antibiotic concentration was used since this was tested for early stage biofilms), a
total of 99.7±0.1% (p = 0.0008) biofilm cells were killed, corresponding to 83.3±4.5% (p
= 0.05) more than that by tobramycin alone and 66.4±9.1% more than the treatment with
tobramycin and DNase I together (Figure 3.7). Collectively, these findings indicate that
GM-CSF is also effective against biofilm cells if the biofilm matrix is removed.
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Figure 3.7 GM-CSF enhanced the killing of P. aeruginosa PAO1 biofilm cells by
tobramycin and DNase I. P. aeruginosa PAO1 cells in early biofilms (4 h after
inoculation) were treated with (i) 0.17 pM GM-CSF alone, (ii) 20 μg/mL tobramycin
alone, (iii) 0.17 pM GM-CSF and 5 units/mL DNase I, (iv) 20 μg/mL tobramycin and 5
units/mL DNase I, (v) 0.17 pM GM-CSF and 20 μg/mL tobramycin, and (vi) 0.17 pM
GM-CSF, 20 μg/mL tobramycin, and 5 units/mL DNase I for 3.5 h. The amount of BSA
(0.1%) was adjusted to be the same for all samples. Following the treatment, the viability
of persister cells was determined by counting CFU. Tob: tobramycin. The samples were
tested in triplicate (n=3). Error bars represent SD; * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001, one-way ANOVA followed by Tukey test.

3.4.5 Alginate lyase allows the diffusion of GM-CSF across alginate layer
P. aeruginosa PDO300 biofilm matrix mainly comprises of alginate which can be
degraded by alginate lyase 39,40,53,55-58. Since addition of alginate lyase along with GMCSF and tobramycin enhanced the killing of P. aeruginosa PDO300 biofilm cells, we
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attempted to obtain experimental evidence that the degradation of the alginate layer
promotes the diffusion of GM-CSF. As shown in Figure 3.8, for samples without 100
µg/mL alginate lyase, there was no detectable level of GM-CSF below the alginate layer
after 2 h of incubation, indicating that no significant diffusion occurred. In contrast, when
alginate lyase was added along with 50 ng GM-CSF, considerable amount of GM-CSF
diffused across the alginate later within 1 h. These results indicate that degradation of the
alginate layer promotes the diffusion of GM-CSF.

Figure 3.8 GM-CSF diffused across an alginate layer in presence of alginate lyase.
The figure shows the Western blotting results of GM-CSF diffusion across 0.3% w/v
alginate layer on top of transwell inserts in presence and absence of 100 µg/mL alginate
lyase over a period of 0, 1, and 2 h. The bands indicate GM-CSF detected by anti-GMCSF (primary antibody) followed by anti-mouse IgG (secondary antibody). As a positive
control, 50 ng GM-CSF was added during western blotting. Top: Top of the transwell
insert, Bottom: Bottom of the 12-well plate.

3.4.6 GM-CSF is not effective against planktonic normal cells of P. aeruginosa
PAO1 and PDO300
To understand if the activities of GM-CSF are specific to persister cells, the total
population (without persister isolation, containing more than 99% normal cells) from
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exponential phase and stationary phase cultures of PAO1 and PD0300 were also treated
with GM-CSF following the same procedure. Similar to persister cells, GM-CSF alone
did not affect the viability of PAO1 and PDO300 normal cells (p > 0.1 for all conditions
tested). However, unlike persister cells, GM-CSF did not exhibit any synergistic effects
with antibiotics (ciprofloxacin and tobramycin) in killing normal cells of these two strains
(p > 0.1 for all conditions tested) (Figure 3.9A and B).

Figure 3.9 GM-CSF did not sensitize the normal cells of P. aeruginosa PAO1 and
PDO300 isolated from exponential phase cultures to antibiotics. The total viable cells
were obtained from the exponential cultures of wild-type P. aeruginosa (A) and its
isogenic mucoid mutant PDO300 (B).The cells were treated with GM-CSF alone or with
GM-CSF plus antibiotics as indicated for 3.5 h (all tested at 200 μg/mL). The amount of
BSA (0.1%) was adjusted to be the same for all samples. Following the treatment, the
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viability of normal cells was determined by counting CFU. Cip: ciprofloxacin. Tob:
tobramycin. Tet: tetracycline. Gen: gentamicin. The samples were tested in triplicate
(n=3). Error bars represent SD; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001,
one-way ANOVA followed by Tukey test.

3.4.7 GM-CSF is not effective against the non-pathogenic E. coli K12
Since GM-CSF is a cytokine in host immune systems, we hypothesized that it has
different activities against pathogens and host friendly bacteria. To test this hypothesis,
the above experiments were also conducted with the non-pathogenic laboratory strain E.
coli K12. Unlike P. aeruginosa PAO1 and PDO300, GM-CSF did not exhibit significant
effect either on the planktonic or biofilm cells of E. coli K12. The concentration of each
antibiotic that showed 2 log reduction in CFU of normal cells was selected for this test.
The results showed that GM-CSF was not effective against E. coli K12. For example,
treatment with 0.17 pM GM-CSF did not change the susceptibility of E. coli K12
persister cells to 2 µg/mL ciprofloxacin (p = 0.93) and 70 µg/mL tobramycin (p = 0.95)
(Figure 3.10). These results indicate that GM-CSF is not effective on the non-pathogenic
E. coli K12.
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Figure 3.10 GM-CSF did not sensitize the persister cells of E. coli K12 to antibiotics.
The persister cells were isolated from exponential phase cultures by killing the normal
cells with 100 μg/mL ampicillin for 3.5 h, and then treated with 0.17 pM GM-CSF alone
for 1 h, followed by additional treatment with GM-CSF plus an antibiotic as indicated
for 3.5 h. The amount of BSA (0.1%) was adjusted to be the same for all samples.
Following the treatment, the viability of persister cells was determined by counting CFU.
Cip: 2 µg/mL ciprofloxacin. Tob: 70 µg/mL tobramycin. Tet: 20 µg/mL tetracycline.
Gen: 200 µg/mL gentamicin. The samples were tested in triplicate (n=3). Error bars
represent SD; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, one-way ANOVA
followed by Tukey test.

3.5 Discussion
GM-CSF is a vital cytokine for the host to fight invading pathogens, as it has been shown
previously in studies that reducing the expression of GM-CSF leads to higher bacterial
load and increased mortality of the infected mice 28,29. Champsi et al. 59 also showed that
during bacterial infections, if the macrophages/monocytes are exposed to GM-CSF, the
bactericidal activity of the macrophages/monocytes is enhanced. In addition to the
functions in bacterial clearance, it has also been shown previously that in cystic fibrosis
(CF) patients, the induced cytokines can assist in the survival of polymorphonuclear
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neutrophils (PMNs) 60. Despite the well documented effects of GM-CSF on immune
cells, little is known about the direct effects of GM-CSF on bacterial cells, and the effects
on persister cells have not been investigated to date. The data from this study suggest that
GM-CSF is effective in sensitizing the persister cells of P. aeruginosa towards certain
antibiotics. The co-treatment of GM-CSF with ciprofloxacin or tobramycin exhibited
strong synergistic effects in killing P. aeruginosa persisters while both antibiotics alone
are ineffective against persister cells. Such synergy suggests that GM-CSF may have
previously unknown functions besides the recruitment and activation of leukocytes.
We observed that, compared to the strong activities of GM-CSF in sensitizing
P. aeruginosa persister cells, this cytokine is not effective against the non-pathogenic E.
coli K12. To understand if the effects observed in this study also exist against other
bacterial species, GM-CSF can be tested on other pathogenic and non-pathogenic
bacteria. Most of the pathogenic Gram-negative bacteria express virulence-related outer
membrane proteins, which are required for the bacterial survival within macrophages and
under other immune responses 61. Lin et al. 62 demonstrated that an outer membrane
protein, OprI serves as the receptor for cationic α-helical antimicrobial peptides (AMPs).
It will be interesting to study whether GM-CSF also has an outer membrane protein target
on the P. aeruginosa.
Compared to the potent activities in sensitizing planktonic persister cells of P.
aeruginosa PAO1 and PDO300 to antibiotics, DNase I and alginate lyase were required
for activities on biofilms of PAO1 and PDO300, respectively. This finding suggests that
the biofilm matrix may present a barrier for the penetration of GM-CSF. In cystic fibrosis
patients, during prolonged infection and exposure to antibiotics, some non-mucoid strains
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of P. aeruginosa mutate to convert to mucoid strains, causing alginate overproduction 39.
Mucoid conversion has been shown to be a hallmark of chronic lung infection in cystic
fibrosis patients. The protection of alginate against GM-CSF is consistent with this
observation and provides new insights in the pathogenesis of P. aeruginosa infections.
Our results suggest that developing new delivery strategies to allow GM-CSF to penetrate
the extracellular matrix of biofilms might increase the efficacy of antibiotic therapies.

3.6 Conclusions
Overall, we found that GM-CSF has direct effects on bacterial persister cells. The exact
mechanism of this new phenomenon needs to be further investigated. With high tolerance
to antibiotics, persister cells remain as a major challenge to the treatment of chronic
infections. The results of this study suggest that immune factors have previously
unknown activities against persister cells. Understanding the importance of each cytokine
and knowing the exact mechanism of their actions on bacteria can help understand how
bacteria establish chronic infections and pave the way for developing more effective
treatments.
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CHAPTER 4

INVESTIGATION OF THE EFFECTS OF GRANULOCYE
MACROPHAGE COLONY- STIMULATING FACTOR (GM-CSF)
ON PSEUDOMONAS AERUGINOSA
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4.1 Abstract
As described in chapter 3, GM-CSF was found to sensitize the persister cells of P.
aeruginosa PAO1 to antibiotics, while no such effects were observed for normal cells. In
this chapter, DNA microarray analysis and qPCR were used to study the effects of GMCSF on gene expression in normal and persister cells of P. aeruginosa PAO1. The DNA
microarray results indicated that treatment with 0.17 pM GM-CSF induced the expression
of 19 pyocin-related genes, and 18 chemotaxis/motility genes in persister cells. The
qPCR results confirmed the gene expression of 10 representative genes in persister cells
and 4 representative genes in normal cells, with rpoD (encoding for RNA polymerase
sigma factor RpoD) as a housekeeping gene. The reduction in viability of R2-pyocin
sensitive P. aeruginosa PAK strain indicated that GM-CSF induces R2-pyocin-related
genes in the persister cells of P. aeruginosa PAO1. Approximately 9 genes associated
with multidrug efflux pumps were also found to be repressed in persister cells. On testing
the ATP-binding cassette (ABC) and major facilitator superfamily (MFS) transporter
transcriptional regulator mutants, it was found that MFS transporters probably have a
marginal role in GM-CSF activity.
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4.2 Introduction
In chapter 3, I reported data showing that the persister cells of P. aeruginosa PAO1 were
sensitized to antibiotics by GM-CSF. For example, GM-CSF sensitized the persister cells
of P. aeruginosa PAO1 to ciprofloxacin and tobramycin, while no such effects were
observed for normal cells. To understand the distinct effects of GM-CSF on persister and
normal cells, these two populations were treated with or without 0.17 pM GM-CSF and
the gene expression was studied using DNA microarray analysis, which is a wellestablished technology for studying gene expression at the genome-wide scale 1-3. The
microarray technology involves using glass or silicon chips with microscopic DNA spots
1-4

. Each spot has multiple probes for a particular gene 1-4. By detecting the fluorescent

signals of target cDNA from mRNA, the expression level of each gene can be determined
1,2,4

. DNA microarray allows simultaneous measurement of the mRNA levels of

thousands of genes.
The results of DNA microarray analysis were confirmed using quantitative realtime polymerase chain reaction (qPCR). The qPCR is a powerful method for gene
expression study. By using the intensity of fluorescence emitted during PCR, it allows the
researchers to monitor the abundance of DNA product using PCR reaction 5-7. Thus, one
can compare the amount of target DNA in different samples. The expression levels of the
selected genes were compared between DNA microarray and qPCR results to affirm the
effect of GM-CSF on persister and normal cells.
The DNA microarray studies showed that GM-CSF have different effects on
normal and persister cells of P. aeruginosa PAO1. Specifically, genes associated with
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flagella and pyocins were induced, and genes associated with transporters were repressed
in persister cells, but not in normal cells.

4.3. Materials and Methods
4.3.1 Bacterial strains and growth media
The bacterial strains P. aeruginosa PAO1 8(obtained from Prof. Matthew Parsek) and
PAK 9 were used in this chapter. Individual transposon mutants, PA0620::phoA,
PA0218::phoA and PA3594:: phoA with the transposon insertion ISphoA/hah were
obtained from the P. aeruginosa PAO1 mutant library at University of Washington 10.
Overnight cultures of these strains were prepared in Luria Bertani (LB) medium 11
containing 10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl at 37ºC with shaking at
200 rpm. The transposon mutants were grown in LB medium supplemented with 60
µg/mL tetracycline. Recombinant human GM-CSF (E. coli-derived Ala18-Glu144) was
purchased from R&D systems (Minneapolis, MN, USA). The stocks used in this study
contained 10 µg/mL GM-CSF, dissolved in phosphate buffer saline (PBS) pH 7.4,
supplemented with 0.1% bovine serum albumin (BSA).

4.3.2 DNA microarray analysis
The persister cells of P. aeruginosa PAO1 were isolated from 60 mL overnight cultures
by adding 200 µg/mL ciprofloxacin and incubating at 37ºC for 3.5 h with shaking at 200
rpm. The isolated persister cells were washed with PBS and resuspended in 300 mL PBS.
These persister cells were supplemented with 0.17 pM GM-CSF (treatment) or the same
amount of BSA (0.1%), but no GM-CSF (control). The control and the treatment samples
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were incubated at 37°C for 1 h with shaking at 200 rpm. After incubation, the cells were
quickly collected by centrifugation at 10,000 rpm for 2 min at 2°C. The supernatant was
decanted and the cell pellets were flash frozen in a dry ice-ethanol bath. Then cell pellets
were stored at -80°C until RNA isolation. Total RNA was isolated using RNeasy Mini kit
(Qiagen, Valencia, CA, USA) including on-column DNase treatment, and sent to the
DNA microarray facility at SUNY Upstate Medical University (Syracuse, NY, USA) to
check on a bioanalyzer before hybridization to GeneChip P. aeruginosa Genome Array
(Affymetrix, Santa Clara, CA, USA). GeneChip Operating Software (MAS 5.0) was used
to identify the differentially expressed genes by signal detection based on Wilcoxon
signed rank test and Tukey’s biweight. The fold change for each gene was calculated as a
ratio of treatment to control signals. In comparison, similar DNA microarray analysis was
also performed on the total population from stationary cultures of P. aeruginosa PAO1.

4.3.3 Quantitative real-time PCR (qPCR) analysis
To validate the DNA microarray results, the transcriptional levels of nine representative
genes were also tested using qPCR, including six induced genes (flgF, prtN, fliN,
PA0620, PA0633 and PA0640), two repressed genes (wbpK, algA), and one unchanged
gene (argH). The gene rpoD (RNA polymerase sigma factor RpoD) was selected as
housekeeping gene for the qPCR study as described previously 12. For the regular
population (no persister isolation), qPCR was performed on two induced genes (yrfI,
dnaB) and two repressed genes (PA0364, PA5548) to confirm the microarray results. The
cDNA was synthesized from the isolated RNA of control and treatment samples using
iScript™ cDNA Synthesis Kit (Biorad, Hercules, CA, USA). The primers were designed
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using OligoPerfect™ Designer (Life Technologies, Grand Island, NY, USA) and Primer
blast (NCBI) to obtain products with sizes between 231 and 350 bp, and melting
temperatures between 59.5 and 60.3°C. The sequence and the product size for each
primer pair are listed in Tables 4.1 and 4.2. The qPCR samples were prepared by mixing
cDNA, primers, and iTaqTM Universal SYBR Green Supermix (Biorad, Hercules, CA,
USA). The qPCR reactions were performed using an Eppendorf Mastercycler Realplex
thermal cycler (Eppendorf, Hauppauge, NY, USA). The qPCR reactions underwent the
following cycles: heat activation at 95°C for 2 min, 40 cycles of denaturation at 95°C for
15 s, and annealing/extension at 60°C. A melting curve was added after the PCR cycle as
a dissociation analysis to confirm if the PCR reaction produced only the desired product.
The melting curve was set at 95°C for 15 s, 50°C for 30 s, 20 min hold with temperature
gradient, and 95°C for 15 s. After the qPCR reactions, the expression ratios of the
selected genes were analyzed using LinReg PCR program (Heart Failure Research
Center, Amsterdam, Netherlands).
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Table 4.1 Primers used for qPCR of persister cells.
Primer

Sequence

rpoD Forward

CGGTCAACCTGAAGGACGAT

rpoD Reverse

ACCAGCTTGATCGGCATGAA

flgF Forward

TCAACCCGAACCTGAAGCAG

flgF Reverse

CACCACGCTCAAGTGATTAGC

fliN Forward

GGATGTGATCCTGGACATCCC

fliN Reverse

GCAGCTTCTTGATGCGTTCG

prtN Forward

ACCGTGGAATTGGTCTACCG

prtN Reverse

CTCAGGATGCGATGCTGTCA

PA0620 Forward

TGCTGTCTCGAACAGTAGCG

PA0620 Reverse

AGGAACCTCCAATGTCGCAG

PA0633 Forward

CAGATCTACGCCCTGGTTCC

PA0633 Reverse

TCGTCTCGCCATCTTTCTCG

PA0640 Forward

CGACATATTCAAGCGAGCCG

PA0640 Reverse

AGGTCAGCCCTTTCGATTCC

recA Forward

TCGGAACATTCTTCCCGTCG

recA Reverse

CGATGTCCAGACCCAGGGAG

wbpK Forward

ACAGGTCGATGCTTCCAAGG

wbpK Reverse

CCCCAGGTAGCGACAAATGA

algA Forward

GTCGTCGATCTGGGACGTG

algA Reverse

GGTAGACCTCGCAGTGGTTC

argH Forward

CAGGAAGACAAGGAACCGCT

argH Reverse

GCTGTCTACGCCGTACTTCA

Product size (bp)

253

273

245

271

268

253

240

258

243

263

231
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Table 4.2 Primers used for qPCR of normal cells.
Primer
dnaB Forward

Sequence

Product size (bp)

CGACGTGGAAACCACTCTGA
347

dnaB Reverse

CGATGGTCATGGCGGTAGAA

yrfI Forward

CCCGCATGTCCCATTCAGAT
303

yrfI Reverse

CGATGGACTCCGCCGAATAG

PA5548 Forward

TATTCTTCGTCGGCGTGACC

PA5548 Reverse

TGGTCGGGATGATGATTGCC

PA0364 Forward

AGCTCTCGGTCTACGGTCTT

PA0364 Reverse

GAAAAGCCGTGAAGCACGTT

300

303

4.3.4 Effect of GM-CSF on the induction of pyocin genes in P. aeruginosa PAO1
persister cells.
GM-CSF induced a large number of pyocin-related genes in persister cells of P.
aeruginosa PAO1, which included the pyocin regulatory gene prtN (induced by 2.8-fold)
and R-pyocin (PA0617, PA0619-22, PA0625-30) related genes. Since the R2-pyocins
generated by P. aeruginosa PAO1 cause cell lysis in the R1-pyocin producing strain P.
aeruginosa PAK, an experiment was designed to test the effect of GM-CSF on the
production of R2-pyocins in P. aeruginosa PAO1 persister cells 13. The planktonic cells
were harvested from overnight cultures (16 h after inoculation) of P. aeruginosa PAO1
and PAK grown in 30 mL LB medium. After washing the cells with PBS (pH 7.4) by
centrifuging at 8,000 rpm for 10 min twice at room termperature, the cells were
resuspended in 30 mL PBS and were stored for testing their viability after treatment with
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supernatant obtained by treating isolated persister cells of P. aeruginosa PAO1 with 0.17
pM and 0.17 nM GM-CSF. To isolate persister cells of P. aeruginosa PAO1, the washed
15 mL overnight culture was treated with 200 µg/mL ciprofloxacin for 3.5 h at 37ºC,
with shaking at 200 rpm. Thereafter, the ciprofloxacin was washed away from the
isolated persister cells by centrifugation for three times at 8,000 rpm for 10 min at 4ºC
and resuspended in 15 mL PBS.
To test the effects of GM-CSF on the R2-pyocin production of P. aeruginosa
PAO1, the washed cells were transferred to centrifuge tubes, with 5 mL of washed
persister cells in each tube. GM-CSF was added at 0.17 pM, and 0.17 nM. All samples
included adjusted amount of BSA (0.1%). The samples were incubated at 37ºC for 2 h
with shaking at 200 rpm. The supernatant for testing the presence of pyocins was
collected by centrifugation 13,200 rpm for 5 min. To ensure that the supernatant did not
contain any cells, it was filtered using 0.2 µM nylon filter. The sterile supernatants were
added at a volume of 100 µL to microcentrifuge tubes with a total volume of 1 mL
washed normal cells (~107 cells) of P. aeruginosa PAO1 and PAK, and the samples were
incubated at 37ºC for 3.5 h with shaking at 200 rpm. After washing the cells three times
with PBS, the viability was determined by plating the cells on LB agar plates and
counting CFU using the drop plate method as described earlier 14. For comparison, a
similar experiment was performed with a P. aeruginosa PAO1 strain having a mutation
in the gene encoding for R2-pyocin tail fiber (PA0620::phoA) to test if GM-CSF
treatment on a strain with structurally defective R2-pyocins shows any different effects
on the killing of P. aeruginosa PAO1 and PAK normal cells.
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4.3.5 Effect of GM-CSF on the mutants of ATP-binding cassette (ABC) and Major
facilitator superfamily (MFS) transcriptional regulator
The planktonic cells were harvested from stationary phase (16 h after inoculation)
cultures of ABC (PA0218:: phoA) and MFS (PA03594:: phoA) transcriptional regulator
strains. The persister cells were isolated as described in chapter 3As described previously
in the materials and methods section of Chapter 3 and treated with GM-CSF at 0 and 0.17
pM in the presence and absence of 5 µg/mL ciprofloxacin and tobramycin. The amount
of BSA (0.1%) was adjusted to be the same for all samples so that the effects of GM-CSF
can be studied specifically. The viability of cells was determined by plating the samples
on LB agar plates using drop plate method as described previously 14.

4.4 Results
4.4.1 Effects of GM-CSF on gene expression in P. aeruginosa PAO1
GM-CSF at pM level can sensitize P. aeruginosa persister cells to antibiotics. Since there
was a difference between the effects of GM-CSF on normal and persister populations, we
considered the possibility of GM-CSF affecting the gene expression of these populations
in different ways. To better understand this phenomenon, DNA microarrays were used to
compare gene expression profiles of P. aeruginosa PAO1 persister cells with and without
1 h treatment with 0.17 pM GM-CSF. The results show that a total of 89 genes were
induced and 149 genes were repressed by GM-CSF more than 1.5-fold in both biological
replicates (Figure 4.1A). The induced genes include 34 genes coding for hypothetical
proteins, 19 bacteriophage genes, 10 chemotaxis genes, 8 motility genes, and 18 genes
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with other functions (Figure 4.1A). The repressed genes include 61 genes coding for
hypothetical proteins, 16 genes related to the transport of small molecules, and 12 genes
for transcriptional regulators (Figure 4.1A). Table 4.3 shows the expression fold change
of some representative genes in persister cells based on the DNA microarray results of
two biological replicates. The gene expression patterns showed effects of GM-CSF on
persister cells of P. aeruginosa PAO1. First, a group of genes involved in motility and
flagella were induced, including flgBCDEFGHIJK, fliACDGMN, and cheYZ. In addition,
GM-CSF at 0.17 pM level was found to induce a large number of pyocin genes. For
example, the pyocin regulatory gene prtN was induced by 2.8-fold compared to the GMCSF free control. A large number of R-pyocin (PA0617, PA0619-22, PA0625-30) and Fpyocin (PA0631-35, PA0636-37, PA640) related genes were also induced. The R and F
pyocins are bacteriophages with a tail-like structure 15. Both the R and F-type pyocins can
cause cytoplasmic membrane depolarization in bacteria by pore formation 15. The R-type
pyocins are comprised of an outer sheath, inner core, a baseplate, and 6 tail fibers. While
the F-pyocins are devoid of an outer sheath, they do have a core, baseplate and tail fibers
with short or long filaments 13,15,16. Pyocin production can be provoked by DNA damage,
and it is believed that the pyocinogenic bacteria can gain predominance by producing
pyocins to eliminate pyocin-sensitive species in a mixed bacterial population 17.
There were also a large number of genes repressed in response to GM-CSF. For
example, wbpK (encoding NAD-dependent epimerase/dehydratase), algAL (encoding
alginate related genes), phnA (encoding anthranilate synthase component), and str
(encoding streptomycin 3 -phosphotransferase) were repressed by GM-CSF, suggesting
that cell wall mediated protection and antibiotic resistance may be repressed. The qPCR
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technique was used to validate the DNA microarray results including 10 representative
genes. Consistent results were obtained for 9 of these 10 genes, except for recA which
was induced by 2.2-fold in DNA microarray data but was not significantly changed
according to qPCR results (Table 4.4). For the confirmed genes, flgF encodes the
flagellar rod protein FlgF, which is a part of a group of proteins that form the rod section
of the basal-body assembly of the flagellar motor 18. The rod transmits torque from the
motor through the hook to the flagellar filament, resulting in bacterial motility 19. The
gene fliN encodes a flagellar motor switch protein FliN. FliM and FliN, along with FliG
form a motor switch complex which controls flagellar rotation and direction 20. The
qPCR results showed that treatment with GM-CSF resulted in 3.3- and 8.5-fold induction
in transcription of flgF and fliN, respectively, which is consistent with the DNA
microarray results.
The qPCR results also confirmed the induction of pyocin related genes. PA0620,
which displayed a 5.2-fold induction in qPCR results, encodes a tail fiber protein of R2pyocins 15. PA0633 and PA0640 are F2-pyocin proteins, which showed an induction by
6.5- and 4.7-fold, respectively 16. It was also observed that prtN, a transcriptional
regulatory gene which activates the expression of pyocin genes displayed a 3.3-fold
induction in qPCR results. The prtN gene product interacts with the DNA sequences in
the 5’ noncoding regions (P box) of pyocin genes to activate these genes 21. The induction
of these genes suggests that GM-CSF treatment may enhance pyocin production in P.
aeruginosa PAO1 persister cells, causing them further stress and inducing waking up.
Moreover, qPCR also confirmed the repression of wbpK, encoding an NAD-dependent
epimerase/dehydratase involved in cell envelope biogenesis and catabolism, and algA, an
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alginate biosynthesis gene (encoding mannose-1-phosphate
guanylyltransferase/mannose-6-phosphate isomerase) which produces a precursor for
alginate polymerization 22,23.
To understand if the effects of GM-CSF on P. aeruginosa PAO1 are specific to
persister cells, DNA microarrays were also used to study the effects of 0.17 pM GM-CSF
on the total population (> 99% are normal cells) of P. aeruginosa PAO1 since GM-CSF
only sensitized the persister subpopulation to antibiotics. Using the same 1.5-fold change
as the cut off ratio, 106 genes were found induced and 39 genes were found repressed in
both biological replicates. The induced genes include 44 genes coding for hypothetical
proteins, 11 genes associated with the transport of small molecules, 9 genes related to the
biosynthesis of cofactors, 9 genes encoding putative enzymes, and 8 genes for
transcriptional regulators (Figure 4.1B). Unlike the results of persister cells, there was no
induction of motility and phage related genes in normal cells. Among the repressed
genes, there were 22 genes coding for hypothetical proteins, 4 genes related to
metabolism, 3 genes associated with energy metabolism, and 3 genes encoding for
putative enzymes (Figure 4.1B). The microarray data were validated by qPCR involving
two induced genes (yrfI and dnaB), and two repressed genes (PA0364, PA0558) (Table
4.5). These results indicate the GM-CSF has different effects on the gene expression of
persister cells and normal cells of P. aeruginosa PAO1.
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Figure 4.1 Effect of 0.17 pM GM-CSF on gene expression in P. aeruginosa PAO1.
(A) Number and categories of genes that were consistently induced or repressed in two
biological replicates of P. aeruginosa PAO1 persister cells. (B) Number and categories of
genes that were consistently induced or repressed in two biological replicates of P.
aeruginosa PAO1 normal cells.
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Table 4.3 Expression fold change of representative genes in P. aeruginosa PAO1
persister cells based on the average of two DNA microarray runs.
Gene

flgBFH

Expression fold
Change (GM-CSF
vs. Control)
+(2.1-2.6)

Functions

cheYZ

+(2.1-2.2)

fliN

+2.3

Motility & Attachment; Chemotaxis; Adaptation,

prtN

+2.8

Pyocin regulatory gene

PA0618

+2.8

R-pyocin bacteriophage

PA0619

+2.8

R-pyocin bacteriophage

PA0620

+2.7

R-pyocin bacteriophage

PA0625

+2.8

R-pyocin bacteriophage

PA0633

+3.1

F-pyocin bacteriophage

PA0638

+2.9

F-pyocin bacteriophage

PA0640

+3.1

F-pyocin bacteriophage

PA4593

-15.0

probable permease of ABC transporter

PA0757

-11.5

probable two-component sensor

PA4187

-7.5

probable MFS transporter

PA2408

-5.7

probable ATP-binding component of ABC transporter

phnA

-5.6

anthranilate synthase component I

wbpK

-5

ureA

-4.9

urease gamma subunit

pscR

-4.5

translocation protein in type III secretion

PA1256

-3.9

putative ATP-binding component of ABC transporter

ccmA

-3.7

heme exporter protein CcmA

PA5216

-3.3

iron ABC transporter substrate-binding protein

mmsR

-3.2

transcriptional regulator MmsR

PA4037

-3.0

probable ATP-binding component of ABC transporter

algL

-2.5

poly(beta-D-mannuronate) lyase

algA

-2.5

phosphomannose isomerase / guanosine 5'-diphospho-D-

Motility & Attachment; Cell wall / LPS / capsule
Chemotaxis

NAD-dependent epimerase/dehydratase

mannose pyrophosphorylase
PA4113

-2.1

probable MFS transporter
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Table 4.4 Comparison of qPCR results with the DNA microarray results for 10
representative genes of P. aeruginosa PAO1 persister cells.
Gene

Expression fold change (GM-CSF vs. Control)
DNA microarray

qPCR

flgF

+2.3

+3.3

fliN

+2.3

+8.5

prtN

+2.8

+3.3

PA0620

+2.7

+5.2

PA0633

+3.1

+6.5

PA0640

+3.1

+4.7

recA

+2.2

No significant change

wbpK

-5.0

-2.1

algA

-2.5

-5.9

argH

No significant change

No significant change

Table 4.5 Comparison of qPCR results with the DNA microarray results for 4
representative genes of P. aeruginosa PAO1 normal cells.
Gene

Expression fold change (GM-CSF vs. Control)
DNA microarray

qPCR

dnaB

+8.2

+3.0

yrfI

+4.7

+4.3

PA5548

-5.5

-1.7

PA0364

-11.8

-35.5
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4.4.2 GM-CSF induces pyocin production in persister cells of P. aeruginosa PAO1
R-type pyocins produced by P. aeruginosa strains can be categorized into five types
termed R1 to R5 24. Kohler et al. 13 showed that the R1-pyocin producing P. aeruginosa
PAK strain is susceptible to the R2-pyocins produced by P. aeruginosa PAO1. We found
that treatment with GM-CSF induced R-pyocin related genes in P. aeruginosa PAO1
including PA0617, PA0619-22, and PA0625-30. Further test showed that, after P.
aeruginosa PAO1 persister cells were treated with GM-CSF at 0.17 pM and 0.17 nM, the
supernatant reduced the viability of normal cells of P. aeruginosa PAK by 65.3±14.5% (p
= 0.0201) and 67.8±9.7% (p = 0.0132) respectively compared to the GM-CSF free
control (Figure 4.2A). In contrast, no significant difference (p > 0.1) was observed for the
same treatment of the normal cells of R2-pyocin resistant P. aeruginosa PAO1 (Figure
4.2A). Moreover, when the persister cells of PA0620::phoA,a deletion mutant of PA0620
encoding for R2-pyocin tail fiber protein, were treated with 0.17 pM and 0.17 nM GMCSF, and the supernatant was tested on the normal cells of P. aeruginosa PAO1 and
PAK, no significant change was observed in the viability of cells for both the strains
(Figure 4.2B). These results indicate that pyocins are important for the observed
phenomenon. To our knowledge, the interaction between persister cells and R2-pyocins
has not been explored to date.
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Figure 4.2 Effects of supernatants of GM-CSF-treated P. aeruginosa PAO1 persister
cells. The normal cells harvested from stationary phase cultures of P. aeruginosa PAO1
and PAK were treated with the supernatant collected from the persister cells of P.
aeruginosa PAO1 (A), and PA0620::phoA (B) after treatment with 0.17 pM or 0.17 nM
GM-CSF for 2 h. The amount of BSA (0.1%) was adjusted to be the same for all samples.
Following the treatment, the viability of PAO1 and PAK cells was determined by
counting CFU. The samples were tested in triplicate (n=3). Error bars represent SD; * p <
0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, one-way ANOVA followed by Tukey
test.
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To test the synergistic effect of GM-CSF and antibiotics on PA0620::phoA, a
similar experiment was performed as described in chapter 3, by isolating persister cells
from stationary cultures of PA0620::phoA, followed by treatment with GM-CSF alone or
co-treatment with antibiotics. As shown in Figure 4.3, treatment with 0.17 pM GM-CSF
sensitized 57.2±5.6% (p = 0.0019) and 55.6±6.3% (p = 0.0005) of persister cells to 5
µg/mL ciprofloxacin and tobramycin respectively. In comparison to the wild-type P.
aeruginosa PAO1, a mutation in the R2-pyocin tail fiber gene reduced the synergistic
effects.

Figure 4.3 Mutation in PA0620 (R2-pyocin tail fiber gene) reduced the synergistic
effects of GM-CSF and antibiotics on persister cells isolated from stationary phase
cultures compared to wild-type P. aeruginosa PAO1. The persister cells of
PA0620::phoA were isolated from stationary phase cultures by killing the normal cells
with 200 μg/mL ciprofloxacin for 3.5 h, and then treated with GM-CSF alone or with
GM-CSF plus antibiotics as indicated for 3.5 h (all tested at 5 μg/mL). The amount of
BSA (0.1%) was adjusted to be the same for all samples. Following the treatment, the
viability of persister cells was determined by counting CFU. Cip: ciprofloxacin. Tob:
tobramycin. The samples were tested in triplicate (n=3). Error bars represent SD; * p <
0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, one-way ANOVA followed by Tukey
test.
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4.4.3 Defect in MFS transporter transcriptional regulator shows lower synergistic
activity between antibiotics and GM-CSF compared to wild-type P. aeruginosa
PAO1
GM-CSF treatment repressed the genes associated with ABC and MFS transporters (e.g.
PA2408, PA1256, PA4187, PA4113) in P. aeruginosa PAO1 persisters as shown in
Table 4.3. ABC transporters utilize the energy of ATP hydrolysis to transport substances
including amino acids, ions, peptides, sugars, antibiotics, nutrients, toxins, proteases,
polysaccharides, and other hydrophilic molecules across bacterial membranes 25,26. MFS
transporters use the energy from chemiosmotic gradient of ions instead to carry the
substances including simple sugars, metabolites, drugs, amino acids, ions,
oligosaccharides, nucleosides, etc. across bacterial membranes 27,28. For both the mutant
strains PA0218:: phoA (ABC transporter transcriptional regulator mutant) and PA3594::
phoA (MFS transporter transcriptional regulator mutant), GM-CSF treatment alone had
insignificant effect (p > 0.1) on the viability of persister cells similar to that of the wildtype P. aeruginosa PAO1. GM-CSF was also found to sensitize both strains to
antibiotics. For example, 0.17 pM GM-CSF sensitized the persister cells of MFS
transporter transcriptional regulator mutant PA3594:: phoA to 5 µg/mL ciprofloxacin and
tobramycin by 49.2±10.2% (p = 0.005) and 38.0±9.0% (p = 0.0163) respectively (Figure
4.4). In comparison, ABC transporter transcriptional regulator mutant PA0218:: phoA
persister cells were sensitized by 66.2±41.4% (p = 0.0677) and 75.8±16.3% (p = 0.0025)
(Figure 4.4). The results indicate that MFS transporters have a marginal role in GM-CSF
activities on the persister cells of wild-type P. aeruginosa PAO1.
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Figure 4.4 GM-CSF show marginal reduction in sensitization of the persister cells of
ABC (PA0218) and MFS transporter (PA3594) transcriptional regulator mutants to
antibiotics. The persister cells were isolated from stationary phase cultures of
PA0218::phoA (ABC transporter transcriptional regulator mutant) and PA3594::phoA
(MFS transporter transcriptional regulator mutant) by killing the normal cells with 200
μg/mL ciprofloxacin for 3.5 h, and then treated with GM-CSF plus 5 μg/mL
ciprofloxacin, and 5 μg/mL tobramycin. The amount of BSA (0.1%) was adjusted to be
the same for all samples. Following the treatment, the viability of persister cells was
determined by counting CFU. Cip: ciprofloxacin. Tob: tobramycin. The samples were
tested in triplicate (n=3). Error bars represent SD; * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001, one-way ANOVA followed by Tukey test.

4.5 Discussion
In the DNA microarray studies, we found that a total of 19 pyocin genes including both
R-type and F-type pyocin genes were induced by GM-CSF in P. aeruginosa PAO1
persister cells. The up-regulation of R- and F-pyocin genes suggest that GM-CSF
treatment may induce the production of bacteriocins. R2, F2-pyocin genes and prtN are
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also known to be induced by treatment with ciprofloxacin and hydrogen peroxide 29,30.
Reactive oxygen species (ROS) such as hydrogen peroxide, superoxide, and hydroxyl
radicals are continuously encountered by microorganisms, especially during active
infection with an oxidative stress generated by the host defense 30,31. Thus, we speculate
that GM-CSF might be creating stress on the persister cells. The R-type pyocins have a
higher bactericidal activity than F-type pyocins 15.
The lipopolysaccharides found in the outer membrane of P. aeruginosa cells and
other Gram-negative bacteria act as receptors of R-type pyocins 13,15,32. The killing
mechanism of R-type pyocins involves membrane depolarization by pore formation
13,15,32

. The R2-pyocin genes found induced by GM-CSF are involved in the formation of

base plate (PA0617), tail fiber (PA0619-21), tail sheath (PA0622), and tail (PA062528)33. The R-tpye pyocins with five subgroups: R1, R2, R3, R4, and R5 are similar to
each other structurally, but differ in receptor specificity 34. The R-type pyocins have the
ability to rapidly kill target cells by binding to the bacterial cell surface through their tail
fiber, followed by contraction of the pyocin sheath and penetration of the core through
bacterial membranes 15,17. This leads to depolarization of the cytoplasmic membrane as
the concentrated intracellular ions begin to leak causing cell death 15,17. The tail fiber
protein is required for binding to the receptors of sensitive cells and contraction of tail is
necessary for bactericidal action 35,36.
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Figure 4.5 Structure of R2-pyocin. Adapted from Scholl et al. 17. Copyright, 2009,
American Society for Microbiology.

P. aeruginosa PAO1 produces R2-pyocins that infect R2-pyocin sensitive P.
aeruginosa strains 13,33. The R2-pyocin producing strain and its next generations are
resistant to the produced pyocins 33. It was observed that when the persister cells of P.
aeruginosa PAO1 were treated with 0.17 pM and 0.17 pM GM-CSF for 2 h, the
supernatant collected after centrifugation exhibited cidal effects on the normal cells of
R2-pyocin sensitive P. aeruginosa PAK strain. No such effect was observed on the
normal cells of R2-pyocin producing P. aeruginosa PAO1. These results support the
DNA microarray data which show that GM-CSF induces R2-pyocins related genes
(PA0617, PA0619-22, PA0625-30) 33. F-type pyocins can be categorized into three
subtypes: F1, F2 and F3 16. The induced F2-pyocin genes have structural function in the
formation of tail (PA0635) and baseplate (PA0637, PA0638, PA0640) 30. Moreover, the
gene prtN showed an up-regulation by 2.8-fold in two DNA microarray runs, which was
confirmed by qPCR analysis (3.3-fold induction). This gene encodes an activator of the R
and F-type pyocin genes 21.
Besides the insoluble phage-like R- and F-type pyocins, P. aeruginosa PAO1
also produces soluble S-type pyocins 15. S-type pyocins are colicin-like, protease114

sensitive proteins, consisting of two components: (i) a large component, which shows
killing activity, and (ii) a small component, which is an immunity protein protecting the
host bacteria from killing activity of the large component 37,38. The S-type pyocins
include S1, S2, S3, and AP41 pyocins possessing DNase acitivity, S4 pyocin exhibiting
tRNase activity, and S5 pyocin with membrane damage activity 39,40. However, unlike Rand F-type pyocin genes, the genes associated with S-tpye pyocins did not show a
significant change in expression.
In addition to the induced genes, qPCR also confirmed the repression of wbpK, an
NAD-dependent epimerase/dehydratase gene involved in cell envelope biogenesis and
catabolism, and algA, an alginate biosynthesis gene (mannose-1-phosphate
guanylyltransferase/mannose-6-phosphate isomerase) which produces a precursor for
alginate polymerization 23. King et al. 41 postulated WbpK to be a dinucleotide co-factordependent 4-reductase enzyme which catalyzes the reduction of UDP-4-keto-D-QuiNAc
to generate UDP-D-FucNAc. Moreover, Belanger M. et al. 42 indicated that wbpK plays a
role in O-antigen biosynthesis. The O-antigens are immunogenic, eliciting a strong
antibody response from the infected host 42. They protect the bacteria from phagocytosis
during P. aeruginosa infections 43.
Repression of algA may lead to lowered alginate layer formation, which in turn
could reduce protection against host immune defenses and antibiotics 44. The repression
of algL indicates possible abnormality in the alginate production as the alginate lyase
activity of AlgL is required to degrade mislocalized alginate or mannuronate residues,
which may help explain the enhanced killing by antibiotics 45. In cystic fibrosis patients
with P. aeruginosa infections, pyocyanin is secreted by this bacterium, which is a blue
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redox-active secondary metabolite and generates superoxide and H2O2 in the infected
lungs 46,47. In the pyocyanin biosynthesis pathway, the conversion of chorismate to
anthranilate is catalyzed by anthranilate synthase encoded by phnA and phnB genes 48.
The repression in phnA gene by GM-CSF treatment suggests possibly lowered pyocyanin
production, which may result in reduced virulence.
Multidrug efflux transporters found in Gram-negative bacteria are known to
display a powerful defense mechanism by extrusion of antimicrobial agents and toxins
from the bacterial cells, thus facilitating the survival of bacteria in stressful environments
49,50

. There are five major families of bacterial efflux transporters include: ABC (ATP

binding cassette), MFS (major facilitator superfamily), RND (resistance-nodulationdivision), MATE (multidrug and toxic efflux), and SMR (small multidrug resistance)
50,51

. As shown in Figure 4.5, ABC transporters utilize the free energy from ATP

hydrolysis to pump out the antibiotics, while all other transporters utilize the proton
motive force as an energy source 51,52. These multidrug efflux pumps have broad
antibiotic specificity and elevation of their expression level due to alterations in
physiological or genetic regulations provides high resistance to a variety of antimicrobial
agents 53-55.
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Figure 4.6 Multidrug efflux pumps of Gram-negative bacteria. Adapted from Piddock
et al. 56. Copyright, 2006, American Society for Microbiology.
The repression of genes related to ABC and MFS transporters in P. aeruginosa
PAO1 persister cells after GM-CSF treatment indicates that GM-CSF possibly plays a
role in suppressing the antibiotic resistance systems in the persister cells, rendering them
susceptible to antibiotic treatments. Comparison of intracellular level of antibiotics in
these mutants and the wild-type P. aeruginosa PAO1 in the presence and absence of GMCSF can give a clarification of the role of GM-CSF on the efflux pumps.

4.6 Conclusions
GM-CSF sensitized the persister cells of P. aeruginosa PAO1 to antibiotics. In this
chapter, we characterized the changes in gene expression caused by GM-CSF, using
DNA microarrays and qPCR. The difference in the expression of genes related to pyocins
and transporters in persister cells and normal cells suggest that GM-CSF has profound
117

effects on persisters. The persister cells showed an induction of 19 pyocin related genes,
whereas normal cells showed no significant change in the expression level of these genes.
Moreover, 16 genes related to transport of small molecules were repressed in persister
cells, while normal cells displayed an induction of 11 genes in this category. The reduced
viability of normal cells of P. aeruginosa PAK by supernatant of GM-CSF treated P.
aeruginosa PAO1 persister cells indicates that GM-CSF induced R2-pyocin-related
genes.
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CHAPTER 5

ROLE OF FLAGELLIN (FliC) IN INTERACTION BETWEEN
GRANYLOCYTE MACROPHAGE COLONY-STIMULATING
FACTOR (GM-CSF) AND PSEUDOMONAS AERUGINOSA

Dr. Xiangyu Yao constructed fliC mutant strain of PAO1 (PAO1 ΔfliC) and fliC complemented strain
(PAO1 ΔfliC/pUCPfliC); performed co-immunoprecipitation and cross-linking experiments.
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5.1 Abstract
Our DNA microarray studies performed on normal and persister cells of the wild-type P.
aeruginosa PAO1 revealed that 18 bacterial motility associated genes were induced in
persister cells by GM-CSF, whereas no such change was observed for the motility genes
in normal cells. The protein FliC (flagellin) was identified as the target of GM-CSF
binding after performing co-immunoprecipitation and cross-linking. To confirm that
interaction with FliC is important the activity of GM-CSF, we tested GM-CSF and
antibiotics on the fliC mutant strain PAO1 ΔfliC, and fliC-complemented strain PAO1
ΔfliC/pUCPfliC. Deletion of fliC gene abolished the effects of GM-CSF on P. aeruginosa
PAO1 persisters, which was restored in PAO1 ΔfliC /pUCPfliC. Moreover, GM-CSF
appeared to be more effective on P. aeruginosa cells with resting flagella since the
effects were enhanced in normal cells of PAO1 pretreated with inhibitors of flagellar
motility, and in the normal cells of the flagellar motor mutants. Thus, the presence of
FliC and a suppressed motility, which are generally found in persister cells, appeared to
be necessary for GM-CSF binding and associated activities.
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5.2 Introduction
Flagellum is a highly complex bacterial organelle that appears as a long, filamentous
appendage attached to the cell 1. Flagella are involved in bacterial motility, chemotaxis,
and acquisition of essential nutrients 1. It has been shown previously that flagella
contribute to the virulence of P. aeruginosa 1-3. Flagella also mediate cell adherence,
colonization, and biofilm formation 4-9. Thus it is not surprising that nonopsonic
phagocytosis is mediated by bacterial flagella; e.g. macrophages bind to bacterial flagella
and subsequently clear the bacteria from the host 10,11. The protein flagellin (FliC), is the
primary component of flagella. FliC proteins form the filament of flagella of P.
aeruginosa with a 15-18 nm diameter hollow channel 12-16. The mammalian host cells
detect the flagellin monomers using Toll-like receptor 5 (TLR5), which is involved in
both innate and adaptive immune responses 17-19.
As discussed in chapter 4, treatment of PAO1 persisters with GM-CSF induced 10
chemotaxis genes and 8 motility including flgBCDEFGHIJK, fliACDGMN, and cheYZ.
The finding that GM-CSF at pM level can sensitize PAO1 persisters to antibiotics
suggests that PAO1 may have a binding target of GM-CSF. Previously, Mahdavi et al. 20
showed that the uptake of cytokines TNF-α and IL-8 by Neisseria meningitidis is
facilitated by pilus assembly proteins (PilQ and PilE). In another study, Paino et al. 21
identified a bacterial interleukin receptor I (BilRI) on Aggregatibacter
actinomycetemcomitans, which binds to cytokine IL-1β. Wu et al. 22 reported that IFN-γ
binds to the P. aeruginosa outer-membrane protein OprF and induces quorum sensing
and pyocyanin expression.
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The co-immunoprecipitation (co-IP) results described in this Chapter verified the
interaction between FliC and GM-CSF. Co-IP is a technique for determining the presence
or absence of interaction between two proteins in vitro by using target protein-specific
antibodies to indirectly capture proteins bound to a specific target protein 23,24. The GMCSF-FliC binding was identified when the flagellar fractions isolated from PAO1 were
cross-linked with GM-CSF, and co-IP was performed followed by SDS-PAGE analysis.
To further explore the role of FliC in interaction between GM-CSF and P.
aeruginosa, the gene fliC was deleted from PAO1, and both the deletion mutant and
complemented strain were compared with the wild-type PAO1 for the effects of GMCSF. The synergistic effects between GM-CSF and antibiotics were abolished in absence
of a functional FliC protein, but were restored when fliC was complemented on a
plasmid. Further tests were performed on the wild-type P. aeruginosa PAO1 after
inhibiting the activity of flagella by pre-treatment with inhibitors of protein synthesis and
flagellar activity. It was found that when the flagella of normal cells of P. aeruginosa
PAO1 were made inactive, GM-CSF was able to sensitize them to antibiotics. Since GMCSF did not exhibit any effects on the normal cells with functional flagella (as discussed
in Chapter 3), the inactive/resting flagella are possibly essential for the binding.

5.3. Materials and Methods
5.3.1 Bacterial strains and growth media
P. aeruginosa PAO1 25(obtained from Prof. Matthew Parsek) and PAK 26 were used in
this study. The mutant strains PAO1 ΔfliC (fliC deletion mutant) and PAO1
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ΔfliC/pUCPfliC (fliC complemented strain), were constructed by Dr. Xiangyu Yao in the
Ren lab and used to study GM-CSF activity. Individual transposon mutant of the genes
motD (PA4593::lacZ) and motA (PA4954::lacZ) were obtained from the P. aeruginosa
PAO1 mutant library (from Manoil lab at University of Washington) 27. Overnight
cultures of these strains were prepared in Luria Bertani (LB) medium 28 containing 10 g/L
tryptone, 5 g/L yeast extract, and 10 g/L NaCl at 37ºC with shaking at 200 rpm. The
transposon mutants were grown in LB medium supplemented with 60 µg/mL
tetracycline. PAO1 ΔfliC was cultured in LB medium supplemented with 100 µg/mL
gentamicin and 500 µg/mL streptomycin, while PAO1 ΔfliC/pUCPfliC was cultured in
LB medium supplemented with 150 µg/mL carbenicillin. Recombinant human GM-CSF
was purchased from R&D systems (Minneapolis, MN, USA). The stocks used in this
study contained 10 µg/mL GM-CSF, dissolved in phosphate buffer saline (PBS) pH 7.4,
supplemented with 0.1% bovine serum albumin (BSA). (Z)-4-bromo-5(bromomethylene)-3-methylfuran-2(5H)-one (BF8) was synthesized previously by Dr.
Jiachuan Pan in the Ren lab and stored at 60 mg/mL in absolute ethanol before
experiments.

5.3.2 Isolation of flagella from P. aeruginosa PAO1 cells
In order to isolate the flagella of the wild-type P. aeruginosa PAO1, 100 µL of stationary
phase culture with an OD600 (optical density at 600 nm) around 2.0 was spread on top of
1.5% agar plates, and grown at 37 ºC for 16 h. Approximately 2 mL of PBS was then
added on top of the plates and the cells were collected using a spreader. Cells were
transferred to microcentrifuge tubes and vortexed vigorously for 30 min. Thereafter, the
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samples were centrifuged at a speed of 13,200 rpm for 20 min at 4 ºC to remove insoluble
proteins and separate the flagella from cell pellet 29. When the isolated flagella were used
in the tests on cells, 200 µg/mL ciprofloxacin was added to the collected supernatants and
the samples were incubated for 3.5 h at 37 ºC with shaking at 200 rpm kill all remaining
cells, followed by dialysis against PBS (pH=7.4) at room temperature to remove
ciprofloxacin. Dialysis was performed using dialysis membranes (Spectrum Labs,
Rancho Dominguez, CA, USA) with 3,500 Da as cut-off molecular weight. For testing
the effects of sheared flagella, the resulting solution with flagella was sheared with 0.1
mm diameter zirconia/silica beads (Biospec Products, Bartlesville, OK, USA) for 5 min
(1 min beating followed by an interval of 20 s) at speed setting 48 (~5000 rpm) (MiniBeadbeater-1, Biospec Products, Bartlesville, OK, USA).
Flagella were also isolated for tests of GM-CSF binding, by performing dialysis
against PBS without any ciprofloxacin instead, followed by addition of MgCl2 to a final
concentration of 100 mM for precipitation of isolated flagella. The resulting supernatant
was incubated overnight at 4 ºC to precipitate flagella. The precipitate was collected by
centrifugation at 13,200 rpm for 20 min at 4 ºC and pellet was resuspended in PBS. SDSPAGE/ SYPRO Ruby and Western blotting were performed to assess the purity of
isolated flagella.

5.3.3 GM-CSF binding with cross-linking and Co-Immunoprecipitation (Co-IP)
The inner and outer membrane proteins of P. aeruginosa PAO1were isolated by cell
fractionation method demonstrated by Filip et al. 34 and Portnoy et al. 35. To cross-link
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GM-CSF with P. aeruginosa cells, membrane proteins and isolated flagella fraction, 10
µL of 5 ng/µL GM-CSF was incubated with 30 µL of each sample for 2 h at room
temperature, followed by addition of the cross-linker bissulfosuccinimidyl suberate (BS3)
to a final concentration of 2.5 mM. The cross-linking reaction was performed at room
temperature for 30 min and quenched by 50 mM Tris-Cl (pH 8.0) for 15 min at room
temperature. After mixing with Laemmli sample buffer (2 mM β-mercaptoethanol, 2%
SDS, 10% glycerol, 0.01% bromophenol blue, 62.5 mM Tris-HCl (pH 6.8)) 30. The
samples were analyzed by SDS-PAGE followed by immunoblotting detection or staining
with SYPRO Ruby (Bio-Rad, Hercules, CA, USA). Co-immuniprecipitation was
performed using 165 µL protein A/G magnetic beads (Thermo Fisher Scientific,
Waltham, MA, USA) with 35 µg anti-GM-CSF covalently coupled using BS3 and
conjugation buffer. Meanwhile, 300 ng GM-CSF was cross-linked with 180 µL of
membrane proteins or isolated flagella. After precleaning the GM-CSF-protein mixture
with uncoupled beads for 2 h, immunoprecipitation (IP) was performed on the resulting
supernatant by subjecting it to anti-GM-CSF coupled beads for 2 h at room temperature
with gentle shaking (50 rpm). The protein A/G beads were washed twice with 500 µL IP
buffer (PBS with 0.05% Tween 20) and once with 500 µL PBS containing 0.5% Triton
X-100, followed by incubation with 50 µL Laemmli sample buffer for 5 min at 95ºC.
SDS-PAGE was performed to analyze the samples and proteins were visualized using
SYPRO Ruby staining.
For Western blotting, the proteins were transferred to polyvinylidene difluoride
membranes and blocked with 5% milk in TTBS, followed by desired primary antibody
(anti-GM-CSF, 1:2000; anti-FliC, 1:2000). The secondary antibody incubation was
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performed using anti-mouse IgG conjugated with alkaline phosphatase. The signals were
developed using BCIP/NBT for detection of the alkaline phosphatase activity of
conjugated secondary antibody.

5.3.4 Combined effect of GM-CSF, flagella, and outer membrane vesicles on fliC
mutant, PAO1 ΔfliC
Outer membrane vesicles (OMVs) were tested with GM-CSF and flagella on PAO1 ΔfliC
to see if OMV can facilitate the transport of GM-CSF and flagella, and thus sensitize the
PAO1 ΔfliC cells to GM-CSF. As described by Maredia et al.31, to isolate the OMVs
along with outer membrane proteins (OMPs), an overnight culture of P. aeruginosa
PAO1 grown in LB medium was subcultured to an OD600 of 0.01 in 7 mL LB medium
and incubated at 37 ˚C for 8 h with a shaking at 250 rpm. After the first 2 h, 1 µg/mL
ciprofloxacin was added to the subculture to induce the production of OMVs. The cells
were thereafter removed by centrifugation at 10,000 rpm for 10 min at 4 ˚C. To avoid
contamination of PAO1 cells in the supernatant, it was passed through a 0.2 µM filter. A
centrifugal filter unit (EMD Millipore, Billercia, MA, USA) containing a high recovery
cellulose membrane with 10 kDa as MWCO was used to retain the OMPs and OMVs but
remove the constituents that have a molecular weight below 10 kDa. Up to 12 mL of
filtered supernatant was added to the filtration device, followed by centrifugation at 5,000
× g for 20 min. Desalting procedure was followed by addition of 14.8 mL of 100 mM
NaCl to the 200 µL of concentrated proteins and centrifugation at 5,000 × g for 5 min.
The resultant 200 µL protein solution was given additional 14.8 mL of 10 mM NaCl,
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followed by centrifugation at 5,000 × g for 5 min to wash out the contaminating salts.
The final concentrated 200 µL protein solution was used for experiments.
In order to test whether OMVs and sheared flagella isolated from wild-type P.
aeruginosa PAO1 could restore the effects of GM-CSF to sensitize fliC mutant persister
cells to antibiotics, the persister cells isolated from the stationary phase cultures of PAO1
ΔfliC were treated with (i) 0.17 pM GM-CSF, (ii) 0.17 pM GM-CSF and 100 µL of
sheared flagella, (iii) 0.17 pM GM-CSF and 100 µL of OMVs, (iv) 0.17 pM GM-CSF,
100 µL of sheared flagella, and 100 µL of OMVs, for 3.5 h at 37˚C with shaking at 200
rpm. All of the treated samples were supplemented with 5 µg/mL tobramycin to
determine if synergistic effects exist. After treatment, the cells were washed thrice by
centrifuging at 13,200 rpm for 2 min, followed by CFU counting using the drop plate
method 32 to determine the viability of cells.

5.3.5 Inhibition of flagellar activities
P. aeruginosa PAO1 cells were harvested from overnight cultures grown in LB medium
after incubation at 37ºC for 3.5 h with shaking at 200 rpm. The cells were collected by
centrifuging at 8,000 rpm for 10 min and washed twice with PBS (pH=7.4). The washed
cells were resuspended in 25 mL PBS buffer and vortexed gently for 1 min to release
cells from the aggregates. To inhibit the flagellar activity, the harvested cells were
pretreated with 5 µg/mL BF8 for 3.5 h at 37 ºC with shaking at 200 rpm. Before testing
the effect of GM-CSF, the remaining free BF8 molecules were washed away by
centrifuging twice at 8,000 rpm for 10 min with PBS. To test the effect of GM-CSF, the
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washed cells were transferred to microcentrifuge tubes with 1 mL of washed cells in each
tube. GM-CSF was added at 0.17 pM, and the amount of BSA (0.1%) was adjusted to be
the same in all samples. After treatment at 37ºC for 3.5 h with shaking at 200 rpm, the
cells were washed thrice by centrifuging at 13,200 rpm for 2 min, followed by CFU
counting using drop plate method to determine the cell viability.
Swimming motility assay was performed for normal cells of P. aeruginosa PAO1
treated with different concentrations of BF8 (1, 5, 10, 20, and 40 µg/mL) by adding BF8
to the normal cells and incubating for 3.5 h, followe by growing the cells on 0.3% (w/v)
agar plates for 12 h at 37 ºC as described by Ha et al. 33. Furthermore, viability of normal
cells of P. aeruginosa PAO1 was tested after treatment with BF8 (1, 5, 10, and 20
µg/mL) for 3.5 h at 37 ºC with shaking at 200 rpm. To corroborate the results of BF8,
another experiment was performed by inhibiting protein synthesis (with 256 µg/mL
chloramphenicol for 3.5 h). The normal cells pretreated with BF8 or chloramphenicol
were treated with GM-CSF and antibiotics as described above to study the role of
flagellar motility in persister control by GM-CSF.
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5.4 Results
5.4.1 GM-CSF binds to FliC in P. aeruginosa
Since Co-IP is a technique that helps in determining whether two proteins interact or not
in physiological conditions in vitro, it was performed to find the protein that possibly
binds with GM-CSF. Crosslinking was used to covalently link together possible
interacting proteins, domains, or peptides by forming chemical bonds between specific
amino acid functional groups on biomolecules that occur in close proximity due to their
interaction The co-IP results indicated that GM-CSF binds to the membrane fraction of
PAO1 cells (Figure 5.1A). GM-CSF binding was also detected in the isolated flagella of
wild-type P. aeruginosa PAO1 (Figure 5.1B). Since flagella are anchored to the cell wall
and membrane through basal body component of the flagella, FliC can be found in both
the external appendage and outer membrane vesicles (OMVs). The Western blotting and
SYPRO Ruby staining indicated cross-linked GM-CSF-flagella conjugates.

Figure 5.1 Co-Immuniprecipitation identified FliC as GM-CSF binding target in P.
aeruginosa PAO1. (A) Co-IP eluent of anti-GM-CSF coated beads after incubation with
P. aeruginosa PAO1 membrane protein-GM-CSF cross-linking sample using Western
blotting. (B) Binding was observed between isolated flagellar fraction from P.
aeruginosa PAO1 and GM-CSF, as detected by anti-GM-CSF using Western blotting.
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Comparison between the whole cell lysates wild-type PAO1, PAO1 ΔfliC, and the
complemented strain PAO1 ΔfliC/pUCPfliC verified that FliC is a binding site for GMCSF as the isolated flagellar portion from PAO1 ΔfliC did not show a detectable band as
observed for the wild-type P. aeruginosa PAO1 and PAO1 ΔfliC/pUCPfliC (Figure 5.2).

Figure 5.2 Western blotting showed that GM-CSF binding was abolished in the fliC
mutant strain, but was recovered with complementation of fliC. The whole cell
lysates of wild-type P. aeruginosa PAO1, fliC mutant strain PAO1 ΔfliC, and fliC
complemented strain PAO1 ΔfliC/pUCPfliC were cross-linked with GM-CSF and
detected by anti-GM-CSF.

5.4.2 FliC is important to the effects of GM-CSF on P. aeruginosa persister cells
Using co-IP and proteomics, Dr. Xiangyu Yao in the Ren lab discovered that GM-CSF
binds to the flagellin (FliC) of P. aeruginosa PAO1. The flagellin protein FliC is required
for bacterial adhesion and virulence 8. To verify if FliC is important to the activities of
GM-CSF to sensitize P. aeruginosa persister cells to antibiotics, we repeated the
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experiments described in Chapter 3 with the fliC mutant of P. aeruginosa PAO1 (PAO1
fliC) and the one with complemented fliC (PAO1 ΔfliC/pUCPfliC). As described in
Chapter 3, treatment with 0.17 pM GM-CSF sensitized 61.5±14.5% (p = 0.0003) and
77.1±2.0% (p = 0.0048) of P. aeruginosa PAO1 persister cells to 5 µg/mL ciprofloxacin
and 5 µg/mL tobramycin respectively (Figure 5.3). Such effects were abolished in the
fliC mutant since GM-CSF failed to sensitize stationary phase persister cells of the fliC
mutant to either 5 µg/mL ciprofloxacin (16.5±5.7% (p = 0.0317)) or 5 µg/mL tobramycin
(p > 0.05) (Figure 5.3). Consistently, the activity of GM-CSF was restored when the fliC
gene was complemented using the plasmid pUCPfliC. For example, 0.17 pM GM-CSF
sensitized 80.5±4.7% (p = 0.0004) and 78.1±5.8% (p = 0.0002) of persister cells isolated
from stationary phase culture of PAO1 ΔfliC/pUCPfliC to 5 µg/mL ciprofloxacin and
tobramycin respectively (Figure 5.3).
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Figure 5.3 GM-CSF sensitized the persister cells of P. aeruginosa PAO1 and PAO1
fliC/pUCPfliC isolated from stationary phase cultures to antibiotics, while fliC
persister cells did not get sensitized. The persister cells of P. aeruginosa PAO1, PAO1
fliC/pUCPfliC, and PAO1 fliC were isolated from stationary phase cultures by killing
the normal cells with 200 μg/mL ciprofloxacin for 3.5 h, and then treated with GM-CSF
alone and with GM-CSF plus 5 µg/mL ciprofloxacin or tobramycin for 3.5 h. The amount
of BSA (0.1%) was adjusted to be the same for all samples. Following the treatment, the
viability of persister cells was determined by counting CFU. Cip: ciprofloxacin. Tob:
tobramycin. The samples were tested in triplicate (n=3). Error bars represent SD; * p <
0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, one-way ANOVA followed by Tukey
test.

The aforementioned results of fliC mutant and complemented strain are consistent
with the finding that GM-CSF interacts with FliC and indicate that FliC is required for
synergy in persister killing by GM-CSF and antibiotics. Consistently, we also found that
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the effects of GM-CSF were reduced when the persister cells of P. aeruginosa PAO1
were pretreated with 10 µg/mL anti-FliC for 1 h. For example, GM-CSF sensitized
27.0±9.4% (p = 0.0117) and 57.7±3.5% (p < 0.0001) of persister cells of P. aeruginosa
PAO1 pretreated with and without 10 µg/mL anti-FliC respectively (Figure 5.4). This
observation also supports the presence of GM-CSF-flagella binding.

Figure 5.4 Blocking FliC with the anti-FliC antibody reduced the activity of GMCSF. Persister cells of wild-type P. aeruginosa PAO1were isolated from the stationary
cultures by killing the normal cells with 200 μg/mL ciprofloxacin for 3.5 h. The
harvested persister cells were pretreated with or without 10 µg/mL anti-FliC for 1 h,
followed by treatment with 0.17 pM GM-CSF and 5 µg/mL tobramycin for 3.5 h.
Following the treatment, the viability of persister cells was determined by counting CFU.
The samples were tested in triplicate (n=3). Error bars represent SD; * p < 0.05, ** p <
0.01, *** p < 0.001, **** p < 0.0001, one-way ANOVA followed by Tukey test.

5.4.3 GM-CSF sensitized the persister cells of P. aeruginosa strains with both a-type
and b-type flagellins to antibiotics
The single polar flagella of P. aeruginosa strains express either a-type or b-type flagellins
(FliC), based on the molecular weights of the flagella subunits encoded by fliC and their
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antigenicity 34-37. The a-type flagellin expressed by P. aeruginosa PAK is heterogeneous
and has a variable molecular weight in the range of 45-52 kDa 38,39. The 16 kb genomic
island encoding the determinants of the flagellin glycosylation in the strain PAK contains
14 genes, orfA to orfN, arranged in several putative operons and located between flgL and
fliC 38-40. Schirm et al. 38 reported that the a-type flagellin is glycosylated with a
heterogeneous O-linked glycan attached to Thr189 and Ser260. In comparison, the b-type
flagellin expressed by P. aeruginosa PAO1 is homogenous and has an invariant
molecular weight of 53 kDa 36. The PAO1 strain contains only 4 genes, PA1088-PA1091
(PA1088-PA1090 have unknown functions, PA1091 is a homologue of the rfbC gene that
is 35% identical to the PAK orfN) in the same chromosomal position as 16 kb
glycosylation island found in a-type flagellin producing PAK strain 13. Verma et al. 41
reported that the b-type flagellin produced by P. aeruginosa PAO1 is glycosylated at two
serine residues Ser191 and Ser195.
To understand if GM-CSF has different effects on the strains producing a-type
and b-type flagellins, we also repeated the experiments using the strain P. aeruginosa
PAK. GM-CSF also significantly sensitized the persister cells of PAK to antibiotics. For
example, 0.17 pM GM-CSF sensitized 85.3±4.3% (p < 0.0001) and 80.9±6.8% (p <
0.0001) of the persister cells isolated from exponential phase cultures of PAK to 5 µg/mL
ciprofloxacin and tobramycin, respectively (Figure 5.5A). Similar effects were observed
for stationary phase cultures, with a reduction in 89.3±5.4% (p = 0.0016) and 84.1±2.6%
(p < 0.0001) of persister cells after treatment with 0.17 pM GM-CSF along with 5 µg/mL
ciprofloxacin and tobramycin respectively (Figure 5.5B). As observed for PAO1, GMCSF alone did not affect the viability of PAK persister cells.
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Figure 5.5 GM-CSF sensitized the persister cells of a-type flagellin producing P.
aeruginosa PAK isolated from exponential and stationary phase cultures to
antibiotics. The persister cells of P. aeruginosa PAK were isolated from exponential
phase (A) and stationary phase (B) cultures by killing the normal cells with 200 μg/mL
ciprofloxacin for 3.5 h, and then treated with GM-CSF alone and with GM-CSF plus 5
µg/mL ciprofloxacin or tobramycin for 3.5 h. The amount of BSA (0.1%) was adjusted to
be the same for all samples. Following the treatment, the viability of persister cells was
determined by counting CFU. Cip: ciprofloxacin. Tob: tobramycin. The samples were
tested in triplicate (n=3). Error bars represent SD; * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001, one-way ANOVA followed by Tukey test.
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GM-CSF-flagella binding for a-type flagellin was also confirmed by Western
blotting using the flagella isolated from P. aeruginosa PAK (Figure 5.6). Interestingly,
GM-CSF was found to bind more strongly to PAK flagellin than that of P. aeruginosa
PAO1 (Figure 5.6), suggesting that GM-CSF may have higher binding activity with atype flagellin.

Figure 5.6 GM-CSF binds to both a-type and b-type flagellins. Flagella were isolated
from the wild-type P. aeruginosa PAO1 possessing b-type flagellins and P. aeruginosa
PAK possessing a-type flagellins. The flagella were incubated in the presence and
absence of GM-CSF with cross-linking using BS3, followed with detection by anti-GMCSF.

5.4.4 External addition of flagella and outer membrane vesicles (OMVs) partially
restored the activity of GM-CSF on the fliC mutant
Outer membrane vesicles (OMVs) are produced by Gram-negative bacteria and are
known to contain biologically active proteins 42-44. OMVs, composed of outer membrane
and periplasmic constituents, act as secretory vehicles for proteins, lipids, and PAMPs 44143

48

. OMVs formed by bulging outer membrane and subsequent fission, are involved in

multiple functions including establishing a colonization niche, virulence, transformation,
biofilm formation, mediation of bacterial envelope stress, and modulating host defense
and response 42,49-52. As discussed above, mutation of fliC abolished the ability of GMCSF to sensitize P. aeruginosa persister cells. We were curious if addition of external
flagella along with OMVs and OMPs (outer membrane proteins) of wild-type P.
aeruginosa PAO1 will show any change. We hypothesized that the OMVs can help
deliver flagellins into PAO1 ΔfliC cells, and restore some of the activity of GM-CSF and
antibiotic. However, co-treatment with 0.17 pM GM-CSF, isolated PAO1 flagella, and
PAO1 OMVs sensitized 40.0±12.6% (p = 0.0011) of persister cells from stationary
culture of PAO1 fliC to 5 µg/mL tobramycin (Figure 5.7). The co-treatment reduced the
viability of persister cells by 38.6±12.9% (p = 0.0016) compared to GM-CSF treatment
alone (Figure 5.7). Even though there was a significant increase in synergy between GMCSF and antibiotic, when GM-CSF was added to PAO1 fliC persister cells
supplemented with flagella and OMVs, the change was rather minor. Thus the original
flagellin seems to be necessary for GM-CSF binding.
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Figure 5.7 Additions of isolated flagella and OMVs partially restores the effects of
GM-CSF on the persister cells of the fliC mutant PAO1 fliC. The flagella and OMVs
were isolated from the wild-type P. aeruginosa PAO1. The persister cells of fliC mutant
PAO1 ΔfliC were isolated from stationary phase normal cells with 200 μg/mL
ciprofloxacin for 3.5 h, and then treated with 5 µg/mL tobramycin plus 0.17 pM GM-CSF
(i), 0.17 pM GM-CSF and isolated flagella (ii), 0.17 pM GM-CSF and OMVs (iii) or 0.17
pM GM-CSF, isolated flagella, and OMVs (iv), for 3.5 h. The amount of BSA (0.1%)
was adjusted to be the same for all samples. Following the treatment, the viability of
persister cells was determined by counting CFU. Tob: tobramycin. The samples were
tested in triplicate (n=3). Error bars represent SD; * p < 0.05, ** p < 0.01, *** p < 0.001,
**** p < 0.0001, one-way ANOVA followed by Tukey test.
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5.4.5 Inhibition of flagellar activity enabled GM-CSF to sensitize the normal cells of
P. aeruginosa PAO1 to antibiotics
GM-CSF induced flagellar genes in PAO1 persister cells, but not normal cells (Chapter
4). Because normal cells have actively rotating flagella, we hypothesize that binding of
FliC and GM-CSF is reduced on normal cells, and this inactivation of flagellar motility
may enhance the activity of GM-CSF on normal cells of PAO1. To test this hypothesis,
(Z)-4-bromo-5-(bromomethylene)-3-methylfuran-2(5H)-one (BF8), synthesized by a
former Ren lab member Dr. Jiachuan Pan, was used to inhibit the flagellar activity of
normal cells of P. aeruginosa PAO1. After performing swimming assay with different
concentrations of BF8 (1, 5, 10, 20, and 40 µg/mL) on normal cells of P. aeruginosa
PAO1 (Figure 5.8A), and testing the viability of cells after treatment with BF8 (1, 5, 10,
and 20 µg/mL) (Figure 5.8B), it was found that up to 5 µg/mL BF8 can successfully
inhibit the swimming activity without any significant effect on cell viability.
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Figure 5.8 BF8 inhibited the motility of P. aeruginosa PAO1. (A) Swimming motility
assay of P. aeruginosa PAO1 in 0.3% (w/v) agar plates. (B) Viability of total viable cells
of P. aeruginosa PAO1 after treatment with 1, 5, 10, and 20 µg/mL BF8 for 3.5 h. The
sample were tested in triplicate (n=3). Error bars represent SD; * p < 0.05, ** p < 0.01, ***
p < 0.001, **** p < 0.0001, one-way ANOVA followed by Tukey test.

Thus, to lower the activity of flagella, normal cells of P. aeruginosa PAO1 were
pretreated with 5 µg/mL BF8 for 3.5 h, followed by treatment with GM-CSF and
antibiotics. Interestingly, GM-CSF sensitized the BF8 pretreated normal cells of P.
aeruginosa PAO1 to 5 µg/mL ciprofloxacin and tobramycin by 45.2±3.2% (p = 0.0135)
and 40.3±10.8% (p = 0.0042) respectively (Figure 5.9A). No such effects were observed
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without BF8 pretreatment, no significant sensitization (p > 0.05). To corroborate the
results, a similar experiment was performed by pretreating the normal cells of P.
aeruginosa PAO1 with 256 µg/mL chloramphenicol (instead of BF8), an antibiotic that
interacts with the 50S subunit of ribosome and interferes with the formation of peptide
bonds, thus inhibiting protein synthesis 53,54. The concentration of chloramphenicol used
was the MIC determined in our laboratory. The inhibition of protein synthesis leads to
reduced flagellar activity. It was found that GM-CSF sensitized 49.0±18.0% (p = 0.0060)
and 43.2±7.5% (p = 0.0142) of chloramphenicol-pretreated normal cells of P. aeruginosa
PAO1 to 5 µg/mL ciprofloxacin and tobramycin respectively (Figure 5.9B), compared to
the cells without pretreatment. These results indicate that the interaction between GMCSF and bacterial flagella is important for its activity in synergistic killing of bacterial
cells with antibiotics. It also suggests that GM-CSF is more effective in binding to resting
flagella.
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Figure 5.9 GM-CSF sensitized the normal cells of P. aeruginosa PAO1 isolated from
stationary phase cultures when flagellar activity was inhibited. Normal cells of P.
aeruginosa PAO1 were isolated from stationary phase cultures and pretreated with 5
µg/mL BF8 (A), or 256 µg/mL (B) for 3.5 h. The pretreated cells were then treated with
0.17 pM GM-CSF in the absence or presence of 5 μg/mL ciprofloxacin or 5 μg/mL
tobramycin for 3.5 h. The amount of BSA (0.1%) was adjusted to be the same for all
samples. Following the treatment, the viability of PAO1 cells was determined by
counting CFU. Cip: ciprofloxacin. Tob: tobramycin. The samples were tested in
triplicate (n=3). Error bars represent SD; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p <
0.0001, one-way ANOVA followed by Tukey test.
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The flagella based motility is controlled by a complex ion driven motor situated in
the bacterial cell envelope 55-57. The motor allows the clockwise and anticlockwise
rotation of the flagella 55-58. P. aeruginosa PAO1 contains dual sets of motA and motB
genes (motAB), motC and motD (motCD), and an individual motY gene, that are involved
in the motor functions

59,60

. We found that GM-CSF was able to sensitize the normal

cells in stationary phase cultures of motor mutants motA::lacZ and motD::lacZ to
antibiotics. For example, 0.17 pM GM-CSF sensitized 29.6±6.6% (p = 0.0063) and
28.3±13.8% (p = 0.0475) of normal cells of motA::lacZ to 5 µg/mL ciprofloxacin and
tobramycin respectively (Figure 5.10). The other motor mutant motD::lacZ also displayed
a similar trend with 36.5±5.1% (p = 0.0076) and 29.3±9.6% (p = 0.0169) of persister
cells sensitized by 0.17 pM GM-CSF to 5 µg/mL ciprofloxacin and tobramycin
respectively (Figure 5.10). The strains lacking motA or motD have flagella that are
unable to function as efficiently as the wild-type P. aeruginosa PAO1. Even though GMCSF sensitized the normal cells of motA::lacZ and motA::lacZ significantly, the killing
was not strong. This can be explained by the results reported by Doyle et al. 59 which
show that mutation in motA or motD affects swimming motility, but does not abolish it.
Kato et al. 61 also reported that the insertion mutants of motA and motB were motile.
Collectively, these data further indicate that GM-CSF binds to resting flagella more
effectively.
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Figure 5.10 Reduction in flagellar motor activity due to mutations in motA and motD
allows GM-CSF to sensitize the normal cells of P. aeruginosa to antibiotics. The
normal cells of motor mutants motA::lacZ and motA::lacZ were isolated from stationary
phase cultures and then treated with GM-CSF plus 5 μg/mL ciprofloxacin (A) or 5
μg/mL tobramycin (B) for 3.5 h. The amount of BSA (0.1%) was adjusted to be the same
for all samples. Following the treatment, the viability of normal cells was determined by
counting CFU. Cip: ciprofloxacin. Tob: tobramycin. The samples were tested in
triplicate (n=3). Error bars represent SD; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p <
0.0001, one-way ANOVA followed by Tukey test.

5.5 Discussion
Human cytokines play a critical role in protection against bacterial infections and are
actively involved in proinflammatory/anti-inflammatory symptoms in the host during
infections like fever, swelling, fatigue, etc. 62-65. In Chapter 3, I have shown that
recombinant human granulocyte macrophage colony-stimulating factor (GM-CSF) can
significantly reduce the persistence of P. aeruginosa following antibiotic treatments. To
initiate an infection, P. aeruginosa needs to break the first-line of host defense and
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colonize host tissues with its external appendages, such as type IV pili, fimbria, and
flagella, along with non-pilus adhesins 66-70. Besides other intracellular virulence factors
like OMPs and lipopolysaccharide, several extracellular virulence factors including
secreted toxins, proteases, hemolysins, and enzymes are involved in the pathogenesis of
P. aeruginosa 71,72. In addition, special spherical structures known as outer membrane
vesicles (OMVs), with a diameter around 20-250 nm are released from outer membranes
and serve as virulence mediators to carry toxins, proteases, and other proinflammatory
molecules like flagellin and peptidoglycan to defend ecological niche against competing
bacterial species and leads to release of cytokines which invokes inflammatory host
response 50,73-76.
The DNA microarray studies on the persister and normal cells of wild-type P.
aeruginosa PAO1 after GM-CSF treatment indicated an induction of flagella-associated
genes in persister cells, whereas the normal cells displayed little or no change in these
genes (Table 5.1). Since GM-CSF was able to sensitize only the persister cells to
antibiotics but not the normal cells, the difference in flagella in these populations is of
interest. Bacterial adhesion mediated by flagella is a critical step of switch from motile to
sessile state 8.
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Table 5.1 Expression of some flagella associated genes in normal and persister cells
of P. aeruginosa after treatment with GM-CSF.
Gene

Expression fold change

Functions

Normal
cells

Persister
cells

flgB

-1.3

+2.1

Basal body rod

flgC
flgD

-1.7
NC

+1.7
+1.9

Basal body rod
Hook cap scaffold

flgE

-1.4

+2.0

Hook

flgF
flgG

-1.4
-1.1

+2.3
+2.0

Basal body rod
Basal body rod

flgH

-0.1

+2.6

Basal body L ring

flgI

NC

+1.7

Basal body P ring

flgJ

NC

+1.7

Flagellum specific muramidase

flgK

NC

+2.0

Hook-filament junctional protein

flgL

+1.3

+1.7

F-pyocin bacteriophage

fliA

-1.2

+2.0

σ28sigma factor

fliC

-0.1

+1.7

Flagellin

fliD

-0.3

+1.7

Filament cap, mucin adhesin

fliG

+0.1

+1.5

Motor/switch, mounted onto MS ring,

fliH

NC

+2.6

Negative regulator of FliI

fliM

-1.2

+1.8

Motor/switch

fliN

-0.1

+2.3

Motor/switch

cheY

NC

+2.1

Switch regulator

cheZ

NC

+2.2

CheY phosphatase

fleN

-1.7

+1.8

Flagellar number regulator

153

Figure 5.11 Structure of a typical Gram-negative bacterial flagellum and its
components. Reproduced from Chevance et al. 77 with permission. Copyright, 2008,
Nature Reviews Microbiology.

Figure 5.11 shows a typical bacterial flagellum. In Gram-negative bacteria, the
flagellar structure comprises of a basal body which consists of four rings, L, P, MS and C
1

. The flagellar genes induced by GM-CSF are involved in flagellar basal body proteins

(FlgB, FlgC, FlgF and FlgG), flagellar basal body rod modification protein (FlgD),
flagellar basal body L-ring protein (FlgH), flagellar basal body P-ring protein (FlgI),
flagellar hook protein (FlgE), flagellar hook associated protein (FlgK) and flagellar rod
assembly protein (FlgJ) 78. The induced genes fliACDGMN and cheYZ are also associated
with the flagellar activities. FliA is a RNA polymerase sigma factor for flagellar operon,
induced by 2-fold in persister cells; while fliC was also upregulated by 1.7 fold in
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persister cells but not changed in normal cells. FliC is a b-type flagellin for P. aeruginosa
PAO1, which polymerizes to form the filaments of flagella 41,79. Flagellin is the structural
protein that forms helical chains around the hollow core of the flagellar filament and acts
as a virulence factor that elicits host innate immune response 18,80. Innate immune
response to pathogen-associated molecular patterns (PAMPs) plays a significant role in
early defense against pathogens; and the P. aeruginosa flagellin is one of the main active
PAMPs, which means flagellin can invoke host immune response 81. FliD forms the
flagellar capping protein 82. FliG, FliM and FliN form a motor switch complex, located at
the base of the basal body 83. The chemotaxis proteins CheY and CheZ interact with this
complex, determining the clockwise/counterclockwise direction of the flagellar rotation
83

. The clockwise rotation of flagellar motor is a result of binding of phosphorylated

CheY (CheY-P) to FliM, causing tumbling of the cell 83,84. In the absence or at low
concentrations of CheY-P, the flagellum typically continues with counterclockwise
direction of rotation 83,84. The induction of the genes associated with flagellar structure,
flagellar motor switch and chemotaxis suggests that GM-CSF may induce cellular
motility of persister cells, allowing them to escape the attack of immune cells. Based on
previous studies, the genes flgBCDEFGHIJK, fliACDGMN and cheYZ were observed to
be down-regulated when P. aeruginosa PAO1 was treated with 1 µg/mL ciprofloxacin
and 10% sputum from cystic fibrosis patients 85,86. The induction of flagellar motility
suggests that GM-CSF may disturb the stress response of P. aeruginosa and thus
sensitize persister cells to antibiotics and other host immune factors.
The genes involved in energy production and flagella synthesis have been
previously shown to be downregulated in persister cells compared to exponentially
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growing cells 87. The ability of GM-CSF to induce expression of 18 motility and
chemotaxis related genes in persister cells possibly suggests that this cytokine may
activate flagellar synthesis in otherwise dormant persister cells. This might lead to partial
“wake up” and increase certain cellular activities, thus reducing the antibiotic tolerance.
Moreover, in this study we also showed that FliC is required for GM-CSF binding based
on co-IP results and the mutant study. Each flagellum of P. aeruginosa contains 20,000
units of FliC 88. There was a drastic decrease in the activity of GM-CSF fliC mutant of P.
aeruginosa PAO1. The finding was further confirmed when the mutation in PAO1 fliC
was complemented with plasmid-borne fliC gene. Consistently, when the persister cells
of the wild-type P. aeruginosa PAO1 were pretreated with anti-FliC, synergistic effects
between GM-CSF and antibiotics in persister killing was reduced significantly. These
complementary experiments demonstrated that FliC is required for the activity of GMCSF in persister control.
Since the normal cells also have flagella but were not sensitized to antibiotics by
GM-CSF, we hypothesized that the resting flagella are targeted by GM-CSF. Indeed,
when the normal cells pretreated with chloramphenicol (an antibiotic that inhibits protein
synthesis) or BF8 (an inhibitor of quorum sensing and motility), GM-CSF sensitized a
significant portion of normal cells to antibiotics, although the activity was lower than that
observed for persister cells. It will be interesting to study if any subtle changes exist in
flagella (e.g. protein modifications) between normal and persister cells. Bacterial flagellar
motility enables the host phagocytes to bind and engulf P. aeruginosa 89. The loss in the
bacterial motility observed in clinical isolates from chronic infections due to elevated
persistence help the bacteria to evade identification and ingestion by phagocytes both in
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vitro and in vivo 89. The suppressed flagellar motility helps bacteria to escape
phagocytosis. The results from our study suggest that GM-CSF, which is a cytokine
produced by phagocytes, may help kill persister cells by inducing flagellar expression
and triggering them to revert to antibiotic sensitive normal state. It will be interesting to
test if similar synergy exists with host produced antimicrobial peptides.
Bacterial flagellum has a basal body, which consists of a motor embedded in the
cell envelope comprising an outer membrane ring (L), a periplasmic ring (P), an internal
membrane ring (MS), a cytoplasmic ring (C), and a rod that traverses the periplasmic
space 88,90-92. The basal body also consist of a flagellar motor with two major components
named as stator and rotor. The stator made from proteins MotA and MotB, is attached to
the peptidoglycan and remains stationary. However, the rotor which consists of FliG
protein attached to MS ring with Mot proteins, is involved in the process of torque
generation 88,93-96. Additionally, a motor switch is also present as a part of basal body
structure, consisting of proteins FliG, FliM, and FliN 56,97. The switch is responsible for
the counterclockwise and clockwise direction of the motor 98. FliG is primarily involved
in torque generation, while FliM and FliN interact with chemotaxis proteins 99,100. The
transmembrane protein MotA-MotB complex conducts protons from periplasm to
cytoplasm for the proton gradient driven motor 56,88,101,102. The motor function of wildtype P. aeruginosa PAO1 is controlled by motA, motB, motC, motD, and motY genes 59,60.
We tested the normal cells of motA and motD mutant strains of PAO1 with GM-CSF and
antibiotics. GM-CSF was able to sensitize 36.5±5.1% (p = 0.0076) of persister cells of
motD::lacZ to ciprofloxacin. Doyle et al. 59 demonstrated that the flagellum of P.
aeruginosa PAO1 has a complex configuration, and the loss of a function in a motor
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protein can be compensated by other existing functional motor proteins. For example, it
was reported that in the absence of MotA/MotB, the motility function in taken over by
MotC/MotD and vice versa 59. This complex flagellar motor behavior may explain why
GM-CSF could not effectively bind to the flagella of motA::lacZ and motD::lacZ, which
happen to still retain motility function.
GM-CSF-FliC binding is not specific to just b-type flagellin expressed by P.
aeruginosa PAO1. The cross-linking and cell viability tests on P. aeruginosa PAK
showed that GM-CSF can also effectively bind to a-type flagellin and exhibit synergistic
effects with antibiotics in persister killing significantly. In fact, the heterogeneous a-type
flagellin appeared to have a stronger binding to GM-CSF compared to the homogenous
b-type flagellin according to the cross-linking experiment. However, the synergy between
GM-CSF and antibiotics found to be very similar in P. aeruginosa PAO1 and PAK.
Thus, the distinct glycosylation sites and number of genes involved did not affect the
GM-CSF activity significantly. Since FliC appeared to play a significant role in GM-CSF
activity, we introduced isolated flagella of the wild-type P. aeruginosa PAO1 and outer
membrane vesicles (OMVs) to the fliC mutant PAO1 fliC, to see if any uptake of
external flagellin by PAO1 fliC may restore the activity of GM-CSF. Outer membrane
vesicle production by P. aeruginosa is an important response when this bacterium is
exposed to environmental stresses 48. OMVs are carriers of PAMPs such as LPS and
flagellin, outer membrane proteins, and virulence factors 48. The isolated flagella and
OMVs were able to partially restore the activity of GM-CSF in killing persister cells of
PAO1 fliC with antibiotics. However, the change was relatively small. It is possible that
externally added flagellin did not affect the intracellular target(s) or pathway(s), as it did
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by the original flagellin (FliC) in periplasm, or there might be other pathways affected by
binding of GM-CSF to the native flagella. The exact mechanism by which GM-CCSF
binds to FliC sensitizes persister cells to antibiotics remains unknown and needs further
investigation.
Besides OMVs, rhamnolipids may also help deliver FliC. Rhamnolipids are
biosurfactants composed of mono or di-rhamnose linked to 3-hydroxy-fatty acids of
different length produced by P. aeruginosa during late-exponential and stationary growth
phases 103-106. These glycolipid surface-active molecules possess antimicrobial properties
and show activity against a wide range of microbes including Gram-negative and Grampositive bacteria, fungal species, and viruses 107-111. Gerstel et al.112 reported that
rhamnolipids induce shedding of flagellin from flagella of P. aeruginosa, leading to
recognition of flagellin by epithelial cells and provocation of host immune response. It
would be interesting to treat wild-type P. aeruginosa PAO1 with rhamnolipids, GM-CSF,
and antibiotics together to investigate if any possible rhamnolipid induced shedding of
flagellin and consequent changes might occur in the GM-CSF related effects, GM-CSFflagellin binding, and antibiotic susceptibility of treated cells. Similar experiment can be
performed on the fliC mutant PAO1 fliC with rhamnolipds, GM-CSF, antibiotics, and
isolated flagella for P. aeruginosa PAO1. By exploring new ways to allow GM-CSF to
bind efficiently to both persister and normal cells of P. aeruginosa, we can potentially
improve the activity of GM-CSF in bacterial killing.
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5.6 Conclusions
Flagella are important for bacteria to establish acute infections and are thus detected by
the host for immune response. Based on co-IP and Western analyses, we found an
interaction between the host cytokine GM-CSF and bacterial FliC. We demonstrated that
when the fliC gene is deleted, GM-CSF failed to sensitize the persister cells to antibiotics.
Consistently, complementation of fliC restored the activity. We further demonstrated that
resting flagella are probably necessary for the activity of GM-CSF. When the flagellar
activity was repressed in otherwise motile normal cells of P. aeruginosa PAO1, we
observed an increase in the activity of GM-CSF. Further understanding of how GM-CSFflagellin interaction leads to killing of persister cells by antibiotics will help develop
novel control strategies to combat antibiotic-tolerant infections.
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CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE
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6.1 Conclusions
Bacterial persistence poses significant challenges to the control of bacterial infections,
which are responsible for several health and economic repercussions. Understanding
bacterial pathogenesis and the host immune response to the bacterial invasion can
potentially provide novel strategies to control bacterial persistence. The host immune
system produces cytokines, which are essential signaling molecules that mediate
inflammatory response during the invasion of pathogens. Numerous studies have been
conducted to study the cytokine networks activated in response to various pathogens and
the role of individual cytokines in host response. However, there have been few studies
on the direct interaction between cytokines and bacteria, and no study has been conducted
to investigate the direct interaction between cytokines and persister cells. Here, for the
first time, we show an interaction between bacterial persister cells and granulocyte
macrophage colony-stimulating factor (GM-CSF), a cytokine secreted mainly by
macrophages.
Pseudomonas aeruginosa, an opportunistic Gram-negative bacterial pathogen is
known to exhibit multifaceted mechanisms for acquiring persistence and cause chronic
infections. GM-CSF was found to sensitize persister cells of P. aeruginosa PAO1 to
different antibiotics. GM-CSF enhanced antibiotic susceptibility of P. aeruginosa PAO1
persister cells isolated from both exponential and stationary phase cultures to antibiotics
at different concentrations. When treated with GM-CSF and appropriate extracellular
matrix degrading enzymes, biofilm cells of P. aeruginosa were also sensitized to
antibiotics. Interestingly, the persister cells of non-pathogenic strain E. coli K12 did not
exhibit the same response to GM-CSF.
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In order to understand thi phenomenon, we performed DNA microarray studies
and qPCR analyses. It was evident from the results that genes related to pyocins were
specifically induced in persister cells of P. aeruginosa PAO1 after GM-CSF treatment,
while normal cells displayed no such changes. Consistent with the induction of pyocin
genes, the supernatant collected from the persister cells treated with GM-CSF showed
killing activities against the R2-pyocin sensitive strain P. aeruginosa PAK. The DNA
microarray also indicated an induction in flagellar genes in persister cells, which was not
observed in normal cells. We observed that GM-CSF activity reduced on persister cells in
the absence of fliC gene, and the activity was restored when fliC was complemented. The
presence of interaction between GM-CSF and flagella was verified by CoImmunoprecipitation, and crosslinking experiments.
Overall, this study revealed interactions between the pathogenic bacterium P.
aeruginosa and the human cytokine GM-CSF. Such effects of a cytokine on bacterial
persister cells have not been reported previously. The underlying mechanism deserves
further study. Figure 6.1 summarizes the major findings of this thesis.
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Figure 6.1 A model to explain the observed effects of GM-CSF on P. aeruginosa persister cells. The possible
induction of pyocin production and inactivation of transporters are supported by DNA microarray data. Further tests
are required to validate this model at the protein and cellular levels.

6.2 Recommendations for future work
6.2.1 Effects of GM-CSF on other bacterial species
Our study was primarily focused on the effect of GM-CSF on P. aeruginosa PAO1. It
would be interesting to study some other Gram-negative pathogens, and also Grampositive pathogens. Since GM-CSF was found to interact with flagellin, testing if GMCSF has other binding target in non-flagellated bacterial species will help us understand
the spectrum of targeted bacteria. For example, a Gram-negative opportunistic pathogen
Acinetobacter baumannii is responsible for infections including bacteremia, pneumonia,
meningitis, urinary tract infection, and wound infection. It is a good candidate for testing
the effects of GM-CSF on non-flagellated Gram-negative opportunistic pathogen 1. A.
baumannii lacks flagellar structure and is a non-motile bacterium 2. Klebsiella pneumoni,
which is also a Gram-negative pathogenic bacterium lacking flagella and motility, can be
tested for GM-CSF effects as well 3. Other Gram-negative pathogens such as E. coli
O157:H7 and Enterobacter spp., displaying peritrichous flagella can give more insight on
how GM-CSF can interact with bacterial strains possessing multiple flagella around the
entire bacterial surface 4,5. Studying the effects of GM-CSF on Gram-positive pathogenic
bacteria, such as Listeria monocytogenes and Clostridium difficile lacking L and P basal
body rings in their flagellar structure, may demonstrate differences or similarities
between Gram-negative and Gram-positive bacteria in interactions with GM-CSF 6,7.

6.2.2 Role of GM-CSF during chronic infections
We found that, in the presence of appropriate enzymes that degrade exopolysaccharide
biofilm matrix of P. aeruginosa PAO1 and PDO300, GM-CSF is capable of sensitizing
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the biofilm cells to antibiotics. However, it would be beneficial to reproduce these effects
in cystic fibrosis (CF) airway conditions, which is due to cystic fibrosis transmembrane
conductance regulator (CFTR) dysfunction and mucus hyperproduction 8. The infected
CF airways have a complex configuration due to abnormalities caused by altered mucin
and lipid composition, increased content of proinflammatory cytokines, impaired
mucociliary clearance, dehydrated and infected mucus 9. Growing P. aeruginosa strains
in normal and CF conditions with varying mucus concentrations (2.5% mucus for normal
condition; 8.0% mucus for CF condition) in the medium as described by Matsui et al.10,
and testing clinical isolates for GM-CSF activity can bring us closer to studying animal
models 11.

6.2.3 Therapies with multiple cytokines
During bacterial invasions, multiple cytokines participate in a cascade of events that lead
to host inflammatory response 12. Evaluating the role of individual cytokines, specifically
the ones that have stronger influence in directing the inflammatory response, will reveal
if there are other cytokines that have direct interaction with bacterial persister cells. If an
effective role of cytokines on persistent infections is defined, a multi-cytokine therapy
can potentially lead to an advanced control of bacterial persistence.
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6.2.4 Utilization of STORM as a powerful microscopic tool to visualize GM-CSF
binding.
Stochastic optical reconstruction microscopy (STORM), which is still a relatively new
technology, has the ability to determine ultrastructural features of bacterial cells at
nanoscopic scale, and provide detailed information via imaging 13. This high-resolution
optical microscopy, allows us to view the position of fluorophores with high accuracy for
immunofluorescence imaging 13. Ideal fluorophores for STORM are required to exhibit
brightness with minimal photobleaching in thiol-containing buffers and have a high rate
of photoswitching cycles 14. If GM-CSF labeled with a detectable fluorophore can be
observed at the binding position on flagella, it will provide the most direct evidence of
GM-CSF-flagellin interactions.
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Protocol I
Synergistic effects of GM-CSF and antibiotics on planktonic cells.
1. Grow 50 mL overnight culture (P. aeruginosa PAO1, PDO300, or E. coli K12) in LB
medium.
2. Check OD600 and wash the cells twice by centrifugation at 8,000 rpm for 10 min.
3. Separate the washed culture in equal volumes in two tubes. Select a tube for isolation
of persister cells, and keep another tube for testing the effects of GM-CSF and
antibiotics on the total viable cell population.
4. Add 200 µg/mL ciprofloxacin and treat for 3.5 h at 37˚C, with shaking at 200 rpm.
5. Wash the antibiotic from isolated persisters thrice by centrifugation at 8,000 rpm for
10 min at 4˚C.
6. For both the normal and persister cells population, prepare samples for control and
GM-CSF treatment samples (triplicates). Treat the samples without antibiotics for 1 h
at 37˚C, with shaking at 200 rpm. For the samples with antibiotics, treat for 3.5 h at
37˚C, with shaking at 200 rpm.
7. Wash the samples thrice by centrifugation at 13,200 rpm for 2 min.
8. Perform drop plate method for CFU quantification on 1.5% agar plates.
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Protocol II
Synergistic effects of GM-CSF and antibiotics on biofilm cells.
1. Grow 25 mL overnight culture (P. aeruginosa PAO1, PDO300, or E. coli K12) in LB
medium.
2. Sterilize 316L stainless steel coupons (1.75 cm × 1 cm, 0.05 cm thick) by soaking in
ethanol for 30 min and drying at 50˚C for 15 min.
3. Place the sterilized coupons in empty petri dishes and subculture to an OD600 of 0.01
containing 20 mL LB medium.
4. Grow the 4 h or 24 h biofilms by incubating at 37˚C for 4 h or 24 h without shaking.
5. Wash the coupons gently by dipping in PBS and place in 12-well plates. Prepare
control and treatment samples (triplicates) to a final volume of 2 mL PBS, and
incubate at 37˚C for 3.5 h, without shaking.
6. Wash the coupons gently by dipping in PBS, and transfer the coupons in tubes
individually with 3 mL PBS.
7. Sonicate the coupons (B200, Sinosonic Industrial Co., Ltd., Taiwan) for 4 min to
disperse biofilm cells from the coupons.
8. Vortex for 1 min, and perform drop plate method to quantify CFU on 1.5% agar
plates.
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Protocol III
RNA isolation from normal and persister cells after GM-CSF treatment.
Harvesting cells.
1. Grow 60 mL overnight culture of P. aeruginosa PAO1 in LB medium.
2. Wash the cells twice by centrifuging at 8,000 rpm for 10 min with PBS.
3. Add 200 µg/mL ciprofloxacin and treat the washed cells for 3.5 h at 37˚C, with
shaking at 200 rpm for isolating the persister cells.
4. Wash the persister cells thrice by centrifuging at 8,000 rpm for 10 min at 4˚C with
PBS.
5. Dilute the persister culture 5 times by PBS and divide the diluted culture into 8 tubes.
Each tube contains 37.5 mL diluted persisters (4 tubes for control and 4 tubes for
treatment).
6. Treat the diluted persister culture with different conditions (0.1% BSA for control
samples, and 0.17 pM GM-CSF for treatment samples)
7. Pre cool all the tubes and centrifuges around 0-4˚C.
8. Centrifuge the samples at 10,000 rpm for 2 min at 2˚C and decant supernatant
9. Flash-freeze the cell pellets in dry ice and store at -80oC until used.

RNA isolation using RNeasy Mini Kit (QIAGEN, Valencia, CA).


Preparation

1. Add 200 µL Zirconia/Silica beads to bead beater tube & cool on ice.
2. RLT Buffer: 10 µL of 2-Mercaptoethanol (βME) per 1 mL RLT (2 mL/sample)
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3. RPE Buffer: 8 mL EtOH per 2 mL RPE (4 mL/sample).
4. DNase mix: 45 µL DNase I stock per 315 µL RDD Buffer (360 µL/2 samples).



Isolation
1. Add 450 µL RLT buffer to all the 8 tubes with pellets. After vortexing, combine 2
tubes of control and 2 tubes of treatment. In total, there will be 4 tubes with 900
µL RLT mixed with cells (2 control samples and 2 for treatment samples).
2. Transfer 900 µL of RLT with cells in bead beater tubes with zirconia/silica beads
and beat the samples for 60s (set timer 6) at speed 48 (~5000 rpm).
3. Centrifuge the samples at 13,000 rpm for 15 s at 4ºC. (Keep all centrifugation
steps at these settings unless noted)
4. Collect supernatant, and add 445 µL EtOH.
5. Load 700 µL of sample in RNeasy column (QIAGEN), and centrifuge
6. Add 350 µL RW1, centrifuge twice.
7. Add 180 µL DNase I incubation mix directly onto membrane
8. Incubate at room temperature for 30 min.
9. Add 350 µL RW1, and centrifuge twice.
10. Add 500 µL RPE, centrifuge thrice.
11. Add 500 µL RPE, centrifuge at 13,000 rpm for 2 min
12. Replace collection tube, and centrifuge at 13,000 rpm for 1 min.
13. Place column in a fresh 1.5 collection tube
14. Add 40 µL RNase-free water, centrifuge for 1 min. Collect the flow through and
repeat the step once.
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Quantification

1. Measure optical density at 260 nm (OD260) and 280 nm (OD280), using TE as the
background.
Yield: OD260 of 1.0 = 40 µg/mL.
Ratio of OD260/ OD280 should be higher than 2.0.
2. Check the samples by running them on a 1.4% agarose gel. The samples should have
two clear bands (23S at 3.1 kb, 16S at 1.5 kb). Presence of smear patterns at low
molecular range indicates RNA contamination.
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Protocol IV
Synthesis of cDNA and quantitative polymerase chain reaction (qPCR).


cDNA synthesis using Script™ cDNA Synthesis Kit (Biorad, Hercules, CA).
Components:
mRNA

500 ng

5x iScript Reaction Mix

8 µL

iScript™ Reverse Transcriptase

2 µL

Nuclease-free water

Balance to a final volume of 40 µL

Reaction protocol:
5 min at 25˚C.
30 min at 42 ˚C.
5 min at 85 ˚C.
Hold at 4 ˚C.
Quantification:
cDNA yield (µg/mL): OD260 × 50 µg/mL × dilution factor.



qPCR using iTaq™ Universal SYBR Green Supermix (Biorad, Hercules, CA).
Components
iTaq™ Universal SYBR Green Supermix (2×)

10 µL

Forward and reverse primers (from 10 mM)

0.5 µL each

cDNA template (200 ng/reaction)

5 µL

de-ionized water

4 µL
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qPCR reaction protocol:
Heat activation at 95˚C for 15 s.
Cycle 1-40:
Denaturation at 95˚C for 15 s.
Annealing/extension at 60˚C for 1 min.
Melting curve:
95˚C for 15 s.
50˚C for 30 s.
Hold for 20 min.
95˚C for 15 s.
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